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INTRODUCTION 
 
Congenital heart disease (CHD) encompasses a wide variety of cardiac and vascular lesions, each 
requiring different treatment according to their pathophysiological characteristics. This spectrum of 
malformations can be divided into a limited number of basic pathophysiological categories 
according to the existence of abnormal shunt pathways and obstructions to blood flow (Young 
1980). Many congenital heart defects can be evaluated with echocardiography, and management 
decisions can be based on noninvasive measurements of blood flow patterns and cardiac function 
(Sanders et al 1983). However, in some patients, proper management still requires morphologic and 
hemodynamic evaluation with cardiac catheterization and angiography (Cournand et a1 1953).  
Patients with increased pulmonary blood flow (Q• p) often need surgery at an early age, before 
obstructive pulmonary vascular disease develops (Newfeld et al 1977). Elevated pulmonary 
vascular resistance (PVR) may increase the risk of surgery in patients with CHD (Bando et al 
1996). Therefore, precise information of the patient’s hemodynamic status is essential for optimal 
peri- and postoperative cardiovascular care.  
 
The determination of systemic blood flow (Q• s) and Q• p using the Fick principle depends on 
quantitation of the arteriovenous oxygen content difference (CavO2) across the vascular bed, and 
oxygen consumption (V• O2) values.  Using indirect calorimetry, V• O2 and carbon dioxide 
production (V• CO2 ) values can be determined, when the inspired and expired oxygen (O2) and 
carbon dioxide (CO2) concentrations and the volume of expired gas are known. The V• O2 
measurement may be difficult especially in young children with CHD, so the V• O2 values are often 
estimated from nomograms constructed according to the patient’s characteristics (Wessel et al 1969, 
LaFarge et al 1970, Lindahl 1989). However, the use of linear methods in estimation of the V• O2 
has been shown to result in wide confidence intervals (CI) of the calculated values (Lundell et al 
1996, Sherman et al 1997).  Furthermore, the linear regression equations predicting V• O2 are usually 
based on data obtained from stable subjects undergoing cardiac catheterization, and may not apply 
to a different patient population in other circumstances, e.g. postoperatively in children recovering 
from open-heart surgery. There are no studies of nonlinear modelling in V• O2 prediction.  
9 
 10 
 
 
Acute ventricular failure and pulmonary hypertensive episodes are significant risk factors for 
morbidity and mortality after reconstructive surgery for CHD (Wernovsky et al 1995a, Bando et al 
1995). During open-heart surgery, the pulmonary and coronary circulations are bypassed with 
extracorporeal circulation, exposing the patient to deleterious inflammatory response and 
reperfusion injury (Boyle et al 1997). Despite early surgery, PVR may be elevated after 
cardiopulmonary bypass (CPB), with consequent increase in right ventricular afterload and 
impairment in the performance of both ventricles (Wessel et al 1993, Celermajer et al 1993). 
Furthermore, in many patients, ventriculotomy or coronary artery reimplantation further increase 
the risk of myocardial injury (Castaneda et al 1989). 
  
Several vasoactive regimens have been suggested for postoperative cardiovascular support in 
patients with CHD, but little data exist to support a choice between any specific agents in children 
of different ages and cardiac pathophysiologies. Catecholamines have been widely used to support 
cardiac output after surgery for CHD. They increase cyclic adenosine monophosphate (cAMP) 
resulting in improved myocardial contraction. However, patients with CHD have reduced 
myocardial β-adrenoceptor density, which may affect the efficacy of catecholamines (Kozlik-
Feldmann et al 1993). Furthermore, increased peripheral vascular resistance to blood flow and 
excessive chronotropy associated with catecholamine administration may limit their usefulness in 
some postoperative patients with CHD (Notterman 1991). Systemic vasodilators are also frequently 
used to reduce ventricular pre-and afterload in these patients (Burrows et al 1986, Hopkins et al 
1991). However, hypotension, and increased intrapulmonary shunting are often associated with 
vasodilator administration (Mookherjee et al 1978). The lack of selectivity on pulmonary 
vasculature may also limit their efficacy in patients prone to pulmonary hypertension. 
Phosphodiesterase (PDE) inhibitors improve myocardial performance by increasing cAMP 
independently of β-adrenergic receptors; hence their efficacy should not be compromised by 
adrenergic receptor down-regulation (Skoyles et al 1992). The decrease in systemic vascular 
resistance (SVR) and PVR produced by PDE inhibitors often necessitates preload augmentation to 
avoid systemic hypotension, especially as these agents are relatively long acting. Furthermore, 
studies of neonatal piglet myocardium in fact suggest a negative inotropic effect (Ross-Ascuitto et 
al 1987). Development of thrombocytopenia has also been associated with PDE inhibitor 
administration (Ross et al 1993). Therefore, controlled clinical comparisons of different vasoactive 
regimen are required to choose the most efficient and safe postoperative cardiovascular support in 
neonates and infants with CHD, even though the relative potency of different agents is difficult to 
establish in these patients. 
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Developmental changes in children of different ages affect their response to cardiovascular drugs. 
Maturation of the enzymatic processes of the liver and functions of the kidneys alter metabolism 
and elimination of these agents.  Changes in body composition and protein binding affect the 
volume of distribution (Vd) and clearance (CL) of the drugs (Kearns et al 1989). While 
pharmacokinetics of catecholamines in pediatric patients are widely investigated, studies of PDE 
inhibitor pharmacokinetics in children are more limited (Steinberg et al 1994). 
 
In this study the cardiovascular management in children undergoing reconstructive surgery for CHD 
was evaluated to develop better means of providing hemodynamic support in the immediate 
postoperative period in these patients. The utility of linear regression equations and an artificial 
intelligence neural network (NN) in V• O2 prediction was elucidated by comparing measured and 
predicted V• O2 in a group of children with CHD undergoing preoperative cardiac catheterization. 
The pharmacokinetics of amrinone were examined to ensure adequate amrinone dosing, and to 
clarify the distribution and elimination of amrinone and its metabolites in neonates and infants. 
Finally, the efficacy of amrinone and a combination of dopamine and nitroglycerine for 
cardiovascular support was assessed in neonates and infants after reconstructive surgery for CHD, 
and the safety of these vasoactive regimens was evaluated in these patients. 
 12 
 
 
 REVIEW OF THE LITERATURE 
 
1. Aspects of postoperative care in children with congenital heart disease 
 
1.1. Pathophysiology of congenital heart disease 
 
The function of the immature cardiopulmonary system is limited during the transformation from 
fetal circulation into the adult type of circulation even in the absence of CHD. The hemodynamic 
changes during the first days of life are characterized by functional closure the shunt pathways of 
ductus arteriosus and foramen ovale, and decrease in the elevated PVR secondary to increased 
arterial blood O2 tension (PaO2), decrease of circulating prostaglandins, expansion of the lungs, 
and increased pressure in the left side of the heart  (Moss et al 1964, Emmanouilides et al 1964, 
Arcilla et al 1966, Clyman et al 1977). However, the instability of the newborn circulatory system 
associated with high PVR and right-to-left shunting may continue several days or longer due to 
abnormal stresses as prematurity, hypoxia, CHD and infections (Hickey, Wessel & Reich 1993).  
 
During early infancy, the myocardium is less compliant than in older children secondary to low 
elasticity of the immature contractile myofiber mass (Friedman 1972). Volume overload and 
increased ventricular outflow resistance may lead to ventricular failure, as the noncompliant 
ventricles are restricted in their ability to alter stroke volume (Thornburg et al 1983).  The failure of 
either ventricle results in increased filling pressure, septal shift and decrease in the stroke volume of 
the opposite ventricle due to intimate ventricular interaction during the first months of life (Romero 
et al 1972). The myocardium of a young infant is also more dependent of extracellular calcium than 
that of older children because the sarcoplasmic reticulum stores and releases calcium inefficiently 
(Boucek et al 1984). The incomplete sympathetic innervation of the newborn heart is associated 
with inability to maintain cardiac responses after repeated sympathetic stimulation (Friedman 1972, 
Erath et al 1982). Parasympathetic innervation of the heart is probably complete at birth (Sinha et al 
1973). 
 
The presence of CHD further compromises the performance of the developing cardiovascular 
system.  Even though there are many different kinds of congenital malformations, they can be 
divided into only a few basic pathophysiological categories depending on the existence of abnormal 
shunt pathways or obstruction to blood flow. Pulmonary blood flow may be increased secondary to 
abnormal circulatory pathways between left and right sides of the heart, as in atrial and ventricular 
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septal defect, atrioventricular septal defect (AVSD), and patent ductus arteriosus. These defects are 
associated with volume overload of the heart, and volume or pressure overload of the pulmonary 
circulation (Young 1980). In these patients, an extension in distal muscularization of pulmonary 
arteries predisposes the patients to increased PVR as response to stress (Hoffman et al 1981). In the 
obstructive lesions, e.g. coarctation of the aorta, and aortic and pulmonary stenosis, the ventricular 
workload is increased to overcome the reduced circulation distal to the obstruction. The complex 
defects may involve both partial or total outflow obstruction as well as shunting.  In the complex 
lesions, like tetralogy of Fallot, pulmonary atresia, and tricuspid atresia, Q• p may be decreased, 
resulting in hypoxia. Furthermore, in lesions with common ventricle, transposition of great arteries 
(TGA), and truncus arteriosus, the shunt may be functional, either increasing or decreasing the Q• p 
depending upon the PVR (Young 1980).   Understanding the pathophysiological effects of the 
patient’s cardiac malformation is the key to developing a successful management plan to correct the 
lesion or alleviate its effects on the patient’s health.  
 
1.2. Effects of pre-repair hemodynamics on postoperative circulatory function 
 
Cardiac failure secondary to excessive volume or pressure, or intrinsic alterations in myocardial 
performance, and cyanosis are the major consequences of CHD (Young 1980). In children with 
complete AVSD, congestive heart failure develops early in infancy with increasing left-to-right 
shunting as PVR falls. Atrioventricular valve regurgitation may further increase the ventricular 
volume overload (Bando et al 1995). Increased Q• p may also decrease lung compliance, increase 
airway resistance, and obstruct small airways (Stanger et al 1969, Schindler et al 1995, Lanteri et al 
1995). In these patients PVR rises rapidly, and is usually significantly elevated by the age of one 
year (Newfeld et al 1977). This lesion is often associated with Down’s syndrome. These patients are 
prone to upper airway obstruction, sleep apnea, hypoventilation, and pulmonary infections, which 
also predispose them to pulmonary vascular disease (Spicer 1984, Nespoli et al 1993). Even when 
reconstructive surgery is performed in early infancy, pulmonary hypertensive events may 
complicate the recovery of these patients (Hopkins et al 1991, Bando et al 1995).  
 
Transposition of the great arteries in a neonate is compatible with life only if the parallel systemic 
and pulmonary circulations are connected with a shunt pathway.  In patients with TGA and intact 
ventricular septum, the left ventricle loses its capacity to grow and overcome high afterload as the 
PVR decreases within the first weeks of life. The left ventricular pressure is better maintained when 
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TGA is associated with ventricular septal defect. In these patients, however, the PVR may gradually 
increase, predisposing the child to pulmonary vascular obstructive disease and failure to thrive. 
Therefore, the arterial switch operation is preferable early in the neonatal period to avoid 
postoperative left ventricular failure from increased workload, and chronic pulmonary hypertension 
from excessive blood flow and pressure (Bano-Rodrigo et al 1980, Lecompte et al 1981, Di Donato 
et al 1989). However, these patients are prone to low cardiac output and increased vascular 
resistances during the early postoperative period (Wernovsky et al 1995a, Bryant et al 1998).    
 
Patients with univentricular heart often have hypoxia dependent on the magnitude of Q• p. In these 
patients, the relief of volume overload on the single ventricle after the first-stage palliative 
procedure is accomplished with creation of a direct connection between the systemic venous 
circulation and the pulmonary arteries.  As the pulmonary and systemic circulations are in series 
postoperatively, the resistance to Q• p must be low for efficient systemic ventricular function (Mayer 
et al 1992, Kaulitz et al 1996). Coagulopathies due to polycytemia and increased blood viscosity, 
increased blood volume and systemic to pulmonary collateral vessels may also compromise the 
postoperative course (Henriksson et al 1979, Hetzer et al 1980). 
 
Children with left-to-right shunting and cyanotic heart defects have increased sympathetic activity.  
Secondary to this elevated tone, these patients present down-regulation and uncoupling of the 
myocardial and lymphocyte β-adrenoceptors (Ross et al 1987, Kozlik-Friedman et al 1993, Dzimiri 
et al 1995, Wu et al 1996). In the failing heart, the β1-adrenoceptors are mainly affected, while the 
stimulation of mildly uncoupled β2-adrenoceptors may improve the cardiac function (Bristow et al 
1990). The right atrial β-adrenoceptor density has been shown to be lower in patients with severe 
acyanotic and cyanotic CHD when compared to mild acyanotic CHD. Especially low β-
adrenoceptor densities have been found in neonates with aortic stenosis and TGA. In these patients, 
additional significant β2-adrenoceptor down-regulation may be present. Even though partial 
decoupling of the β2-signal transduction in infants and children with severe CHD has been 
suggested, in patients with aortic stenosis and TGA the adenylate cyclase activity beyond the β-
adrenoceptor level has also been shown to be affected, probably due to an increase in the inhibitory 
G-protein levels (Kozlik-Friedman et al 1993). Therefore, the efficacy of β1- as well as β2-
adrenoceptor agonists may be limited in these patients, and drugs augmenting β-adrenergic stimuli 
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beyond the receptor level, as PDE inhibitors, could be of further advantage in postoperative 
cardiovascular support (Feldman et al 1990, Brodde 1991).  
 
1.2.1. Hemodynamic evaluation 
 
The correct timing of reconstructive surgery is essential in patients with increased Q• p or obstruction 
to pulmonary venous flow.  Pulmonary vasoconstriction and fixed pulmonary vascular disease may 
develop unless the surgical correction is performed early enough (Bush et al 1988). Management 
decisions in CHD can often be based on noninvasive measurements of blood flow and cardiac 
function (Sanders et al 1983). However, it is often necessary to perform cardiac catheterization to 
evaluate the morphologic and hemodynamic status of the patient.  
 
The determination of Q• s and Q• p using the Fick principle depends on quantitation of CavO2 across 
the vascular bed, and V• O2 values.  The SVR and PVR are calculated using pressure differences 
across the systemic and pulmonary beds and corresponding blood flow values, even though the 
recruitability of the pulmonary vasculature complicates the use of traditional PVR determinations 
(Fagard et al 1990, Gorback 1990). Using indirect calorimetry, V• O2 and V• CO2  values can be 
determined, when the inspired and expired O2 and CO2 concentrations and the volume of expired 
gas are known. However, anaerobic metabolism, as well as differences in the produced and exhaled 
CO2 may affect the indirect calorimetry measurements (Ferrannini 1988). Methods using a 
pneumotachograph, or a Douglas bag for gas volume determination, an infrared CO2 analyzer, a 
mass spectrometer, as well as a paramagnetic O2 analyzer have been used in V
• O2 determination 
(Wessel et al 1969, Lindahl 1989, Lundell et al 1996). These methods have been demonstrated to 
have small interobservational variation (Lindahl 1989, Lundell et al 1996). However, these 
equipment require frequent calibration to give reliable results. In addition, the measurements may 
be sometimes cumbersome if mechanical ventilation and high a fraction of O2 in inspired gas 
(FIO2) are needed (Nunn et al 1989). Commercial metabolic monitors with direct measurement of 
the difference between inspired and expired O2 concentrations, gas dilution principle for flow 
measurements, and possibility to study both mechanically ventilated and spontaneously breathing 
patients are available (Meriläinen 1987,Takala et al 1989, Weyland et al 1993).  Cuffed tracheal 
tubes to prevent gas loss from the breathing circuit are often necessary for reliable results in 
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mechanically ventilated patients (Chwals et al 1992). The V• O2 measurement may be difficult 
especially in young children, so the V• O2 values are often estimated from nomograms constructed 
according to the patient’s characteristics (Wessel et al 1969, LaFarge et al 1970, Lindahl 1989). 
However, the use of linear methods in estimation of the V• O2 has been shown to result in wide CI of 
the calculated values (Lundell et al 1996, Sherman et al 1997).  Furthermore, the linear regression 
equations predicting V• O2 are usually based on data obtained from stable subjects, and are not easily 
applied to different patient populations in other clinical situations, e.g. after open-heart surgery to 
assess changes in relationship of V• O2 and O2 delivery in response to vasoactive medications.  
There are no studies in which artificial intelligence NN has been used to improve the predictive 
accuracy of the regression equations.  It is a pattern recognition technique that does not assume or 
require a mathematical relationship between the independent and dependent variables.  It consists of 
a set of processing units, which simulate neurons and are interconnected to allow signals to travel 
through the network. The computational power of NN derives from the density and complexity of 
the interconnections, and its ability to learn from experience during the development process (Cross 
et al 1995). 
 
Because the increased resistance to Q• p in patients with CHD has been found to increase the risks of 
reconstructive surgery (Bush et al 1988, Bando et al 1996), the preoperative evaluation of the 
patient should be based on precise information of pulmonary vascular tone and its reversibility. 
Several vasodilating agents, such as 100 % O2, tolazoline, prostacyclin (PGI2) and inhaled nitric 
oxide (NO), have been used to test the reactivity of pulmonary vascular bed preoperatively to 
determine the stage beyond which reconstructive surgery is no longer indicated (Bush et al 1988, 
Roberts et al 1993, Winberg et al 1994, Berner et al 1996, Turanlahti et al 1998). The assessment of 
the actual vasodilator capacity is important because the increased muscularity of the pulmonary 
vasculature may be a reversible lesion (Hoffman et al 1981). In this setting, the accurate 
determination of patient’s hemodynamic status is necessary.  
 
 
 
 
 
1.3.Reconstructive cardiac surgery and early postoperative circulatory function 
 
The primary determinants of the results of successful constructive cardiac surgery are the adequacy 
of surgical repair and myocardial protection (Najafi et al 1969, Kirklin et al 1981). Even though the 
cardiac surgical procedure itself often improves cardiac output, the intraoperative myocardial 
damage may decrease it during the early postoperative period. Cardiac failure due to procedural 
reasons can occur after any cardiac repair, but it is more common after intracardiac operations 
requiring ventriculotomy. It may be the result of incomplete or inadequate operation, mechanical 
problems, such as undrained pericardial bleeding and pleural effusions causing cardiac tamponade, 
myocardial edema and chamber dilatation in a closed chest, and tension pneumothorax (Kirklin & 
Barrat-Boyes 1993). The complexity of surgery predisposes the patients also to postoperative 
bleeding, which may compromise the postoperative cardiovascular stability  (Williams et al 1999a).   
It is often difficult to distinguish between changes in pulmonary performance produced by 
sternotomy, external cooling of the heart, general anesthesia, mechanical ventilation, and CPB, as 
they are all associated with pulmonary atelectasis (Wilcox et al 1988, Jain et al 1991, Weissman 
1999, Cox et al 2000).  However, the deterioration of functional residual capacity, lung compliance, 
venoarterial admixture, and the elevated alveolar-arterial O2 gradient secondary to these changes 
may further impair the postoperative cardiac performance (Weissman 1999). 
 
In patients with AVSD, restoration of a competent left-sided atrioventricular valve, and elimination 
of residual intracardiac communications are critical to the outcome (Bando et al 1995). These 
patients are also prone to transient postoperative nodal rhythms secondary to damage to the 
conductive tissue (Chen et al 1968). In patients with TGA, the origins and distribution of the 
coronary arteries are variable. Adequate coronary blood flow after transfer of the coronary arteries 
to the neoaorta without narrowing or distortion is required for a successful arterial switch operation. 
Unusual coronary anatomy predisposes these patients for complicated postoperative course 
(Wernovsky et al 1995b). Supraventricular and ventricular tachycardias, as well as complete heart 
block may also exist postoperatively and worsen the cardiac performance (Di Donato et al 1989). 
Patients with Fontan operations for single ventricle have high venous pressure in the right atrium, as 
well as in the hepatic and mesenteric vascular beds. This predisposes the patients to pleural 
effusions and high intra-abdominal venous pressure, which may complicate early postoperative 
recovery (Fontan et al 1990, Kaulitz et al 1996). Supraventricular tachycardia, and strokes also have 
been reported after a Fontan procedure (Driscoll et al 1992).  In general, early closure of left-to-
right shunts results in normal ventricular function (Cordell et al 1976, Baylen et al 1977). In patients 
17 
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with preoperatively increased Q• p the surgical correction of abnormal pulmonary hemodynamics 
favorably affects immediate postoperative respiratory mechanics (Lanteri et al 1995).  However, a 
long-standing left-to-right shunt with volume overload and preoperatively increased PVR may 
result in persisting cardiac failure requiring vasoactive medications long after reconstructive surgery 
(Jamarkani et al 1972, Burrows et al 1988).  
 
1.4. Effects of cardiopulmonary bypass on postoperative circulatory function 
 
The inflammatory response associated with major surgery is particularly pronounced after cardiac 
surgery and CPB. The myocardium, pulmonary system, splanchnic bed and kidneys are the most 
important targets that contribute to the postoperative course after cardiac surgery. The blood-
surface-interaction during the CPB has been suggested to be the main trigger for cell injury.  The 
activation of coagulation, the kallikrein system, fibrinolysis, and the complement system, as well as 
the cytokines activate the expression of leukocyte adhesion molecules on the surface of endothelial 
cells. Once adherent to the endothelium, neutrophils release oxygen-derived free radicals and 
cytotoxic proteases, which contribute to the capillary leak resulting in the postoperative 
extracellular volume overload and electrolyte imbalance (Royston 1997, Hill et al 1997a).  
Endotoxemia is also a potent stimulant to further complement activation, and endothelial cell 
activation resulting in the up-regulation of leukocyte adhesion molecules. This may derive from a 
translocation of bacteria from the gut during splanchnic ischemia (Boyle et al 1997). However, 
tissue ischemia, hypothermia, relative hypotension during nonpulsative flow, hemodilution, and 
administration of blood products and pharmacological agents, such as heparin and protamine, may 
affect the inflammatory response (Royston 1997). Despite interindividual variation in the response 
to the inflammation during CPB, neonates and infants, and patients who require long CPB times, 
are especially at risk to systemic effects of endothelial injury (Kirklin et al 1983). 
 
Myocardial injury associated with cardiac surgery is effected by both ischemia and reperfusion 
injury. During ischemia, there is a downregulation in cellular ATP secondary to lack of O2, and 
hydrogen ion and lactate accumulation (McCord 1985). Microemboli, ventricular fibrillation and 
increased histamine production by basophiles may lead to ischemia during the bypass and 
predispose the patient to postoperative arrhythmias and low cardiac output (Buckberg et al 1975, 
Seghaye et al 1996). Reperfusion injury is characterized by intracellular calcium accumulation, and 
subsequent formation of oxygen-derived free radicals after a period of temporary ischemia (McCord 
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1985). The myocardium is affected by the reperfusion injury during the induction phase of 
cardioplegia, intermittent infusions of cardioplegic solution during the CPB, and after the removal 
of the aortic cross-clamp (Vinten-Johansen & Hammond 1993). The free radicals alter the 
sarcolemmal sodium homeostasis resulting in swelling of the myocytes with reduced postischemic 
blood flow and ventricular compliance (Kloner et al 1983). Low postbypass cardiac indexes, 
decreased perfusion necessitating inotropic support after CPB, and inhibition of the myocardial 
contractile response to β-adrenergic stimulation have been shown to correlate with increased levels 
of cytokines and activated complement components (Kirklin et al 1983, Gulick et al 1989, Seghaye 
et al 1993, Hennein et al 1994). The neutrophil adhesion to myocytes by adhesion molecules is 
associated with myocardial reperfusion injury after CPB as well (Byrne et al 1992, Wilson et al 
1993). However, the immature complement receptors and neutrophil migration have been suggested 
to protect neonates with CHD undergoing cardiac operations from postoperative complications, 
even though complement activation is comparable to that in older children (Seghaye et al 1994). 
Large amounts of endogenous NO, possibly secondary to increased levels of inducible NO due to 
exposure to cytokines and endotoxins, have also been implicated in myocardial reperfusion injury 
(Hill et al 1997b). 
 
Ischemic injury to the pulmonary endothelial cells while they are excluded from the circulation 
during CPB, or the exposure of the lungs to the entire cardiac output, as well as the activated 
inflammatory process and decreased white cell deformability may lead to postperfusion syndrome 
in the lung (Wilson et al 1971, Miller et al 1997, Gilliland et al 1999).  Moreover, surfactant 
inhibition, that predisposes the lungs to alveolar and small airway collapse, is suggested to be 
associated with CPB (McGowan et al 1993, Paul et al 1999). In response to ischemia-reperfusion 
injury, hypoxia and exposure to cytokines the endothelial cells lose their ability to promote 
vasodilatation by constitutively expressing relaxant factors as NO, prostacyclin, and adenosine, 
whereas vasoconstriction is further aggravated by release of endothelin, thromboxane A, and 
angiotensin II. This imbalance may contribute to the lung injury in children with pulmonary 
hypertension, whose endothelium-dependent pulmonary artery relaxation is already impaired 
preoperatively, and may deteriorate further with CPB and increased plasma endothelin levels 
(Wessel et al 1993, Celermajer et al 1993, Komai et al 1993, Verrier et al 1996, Morita et al 1996). 
In children with normal or decreased preoperative Q• p a significant increase in the static elastance 
has been demonstrated after CPB, indicating that extracorporeal circulation may have deleterious 
impact on lung function. This may be due to atelectasis, increased extravascular lung water, and 
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release of vasoconstrictive agents (Lanteri et al 1995, Hiramatsu et al 1997). However, non-
endothelium-derived agents such as catecholamines may also influence the pulmonary vascular tone 
in this setting. 
 
Mucosal hypoperfusion, and microvessel occlusion secondary to platelet, leukocyte, and 
erythrocyte aggregation may affect bowel wall permeability to endotoxin, and contribute to the 
activation of the inflammatory response, sepsis, and multiorgan system failure (Andersen et al 1993, 
Biffl et al 1996). The reperfused gut may also induce mast cell activation and priming of circulating 
neutrophils, resulting in pulmonary injury secondary to sequestration of the neutrophils (Koike et al 
1994, Boros et al 1995). The preoperatively impaired gut mucosal perfusion associated with lesions 
with decreased Q• s may further deteriorate after CPB despite adequate surgical correction  (Booker 
et al 1996). Liver is involved in glucose production and lactate clearance, synthesis of plasma 
proteins, immune function, drug metabolism, and clearance of intravascular debris. Alterations in 
these functions affect postoperative recovery of the cardiac surgical patient (Shangraw 1993). Long 
duration of CPB and repair of complex cardiac defects may lead to hepatocellular dysfunction, 
postoperative pancreatitis, and increased lactate levels (Collins et al 1983, Toffaletti et al 1986, 
Fernandez-del-Castillo et al 1991). Even though no specific lactate concentration has been 
demonstrated to predict outcome in pediatric cardiac patients, increased levels are associated with 
complicated postoperative course (Hatherill et al 1997, Munoz et al 2000). Fluid accumulation 
secondary to changes in body temperature, hemodilution, plasma oncotic pressure, interstitial fluid 
pressure and capillary permeability, is related to the duration of CPB, and young age (Cleland et al 
1966, Utley 1993, Simpson et al 1993). Postoperative renal dysfunction is also associated with 
increased plasma levels of complement components, cytokines, and increased release of neutrophil 
granular proteases (Kirklin et al 1983, Seghaye et a 1993). Fluid retention may contribute to the 
postoperative need for diuretics, osmotic and oncotic agents, and vasoactive drugs (Utley 1993). 
 
Young children demonstrate marked stress response secondary to surgery and CPB  (Anand et al 
1990). This response is characterized by suppression of insulin secretion, and increase in 
catecholamines, glucagon, cortisol, growth hormone, ACTH, and vasopressin levels (Weissman 
1990, Anand et al 1990). The increased catecholamine levels may affect systemic and pulmonary 
vasculature postoperatively. Cortisol excess impairs the ability of insulin to stimulate glucose 
utilization and to reduce hepatic gluconeogenesis.  Furthermore, impaired glucose uptake has been 
observed during the early postoperative period. The increased secretion of catecholamines and 
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growth hormone is associated with elevated free fatty acid levels secondary to stimulated lipolysis, 
resulting in impaired myocardial contractility and increased irritability (Hirvonen et al 1978, Vik-
Mo et al 1981, Weissman 1990). The vasopressin-induced vasoconstriction may adversely affect the 
renal, coronary, and splanchnic circulations (Philbin et al 1979). Thyroid hormone levels have been 
shown to decrease during CPB in children with CHD, and this decrease is associated with 
prolonged and complicated postoperative course (Saatvedt et al 1998). 
 
The use of hypothermia during CPB increases myocardial tolerance to the ischemia associated with 
aortic cross-clamp and cardioplegia. Reduction of myocardial O2 demand by using total CPB, 
diastolic arrest, venting of the heart, and controlled reperfusion decreases the mismatch between 
myocardial O2 supply and demand  (Senning 1952, Buckberg et al 1977,Vinten-Johansen & 
Hammond 1993, Gates, Cushen & Laks 1993). The use of hypothermia delays the neutrophil-
endothelial cell adhesion but does not prevent it (De Leist et al 1995). Normothermic perfusion does 
not produce more profound inflammatory response when compared with hypothermic and 
moderately hypothermic CPB (Birdi et al 1999). Hemofiltration and the use of leukocyte-depleted 
blood may decrease plasma levels of complement components and cytokines, and prevent 
reperfusion injury in pediatric patients (Breda et al 1989, Journois et al 1994a, Hayashi et al 2000).   
However, postischemic contractile function may be stunned for a period of time until energy 
production and excitation-contraction coupling recover (Braunwald et al 1982). Increased vascular 
permeability, arterial hypoxemia and ventilation-perfusion abnormalities may further increase the 
PVR, and compromise cardiac performance (Kirklin et al 1983, Burrows et al 1986, Westaby 1987, 
Hopkins et al 1991). Persistent postoperative arrhythmias, while a subtle manifestation of ischemic 
injury, may directly contribute to low cardiac output after surgery (Smith et al 1983).  Moreover, 
the β-adrenoceptor desensitization and uncoupling associated with CHD may be further aggravated 
during CPB, affecting the efficacy of postoperative cardiovascular support  (Schranz et al 1993).  
 
Pharmacokinetics of drugs are also influenced by CPB. Hemodilution, hypothermia, hypotension, 
changes in regional blood flow, acid-base status, exclusion of the lungs from the circulation, as well 
as possible sequestration of the drug in bypass equipment may affect the drug pharmacokinetics and 
pharmacodynamics (Rosow 1993).  The degree of plasma protein binding, and Vd of the drug may 
have effect on the drug concentration during the bypass. Decreased hepatic and renal blood flows 
may impair the metabolism and excretion of the drugs, and changes in acid-base status may affect 
their distribution. After re-establishment of the pulmonary circulation the pharmacological effects 
 22 
 
 
of drugs with uptake in lungs may be increased (Mets 2000).  These changes may contribute to the 
postoperative hemodynamics in patients undergoing cardiac surgery. 
 
1.5. Anesthetic management and postoperative circulatory function  
 
The goals of the anesthetic management of a child with CHD are to assure a comfortable intra- and 
postoperative course, provide cardiovascular stability, and attenuate the stress response to noxious 
stimuli. Hormonal and metabolic stress responses to cardiac surgery and CPB have been shown to 
correlate with postoperative morbidity and mortality in neonates despite hemodynamic stability 
(Anand et al 1990, Anand et al 1992). As the patients with complex CHD have limited myocardial 
reserve postoperatively, stressful interventions may further compromise cardiopulmonary function. 
Pain, wakefulness and agitation may lead to pulmonary hypertensive crises and sudden death after 
reconstructive surgery in patients with pulmonary hypertension (Hopkins et al 1991). The extension 
of anesthetic period postoperatively and ventilatory control to avoid hypoventilation and acidosis 
have been associated with reduced postoperative morbidity in high-risk patients (Wernovsky et al 
1995a, Wernovsky et al 1995b, Bando et al 1996). 
 
The choice of anesthetic agents depends on the preoperative cardiovascular status of the patient.  
Young children with complex CHD associated with decreased myocardial reserve, intracardiac 
shunting, or compromised forward flow require different anesthetic management than older, 
asymptomatic children with noncomplicated defects in whom fast postoperative recovery is 
expected.   Inhalation anesthetics that may be safely used in some uncompromised patients with 
CHD are often not well tolerated in critically ill infants due to their depressant effects on 
myocardium (Kawana et al 1995). Intravenous ketamine provides hemodynamic stability in 
children with CHD, even though increase in PVR has been suggested in adult cardiac patients with 
unprotected airways (Spotoft et al 1979, Hickey et al 1985b). It improves gas exchange and chest 
compliance in patients with small airway obstruction that may be associated with increased Q• p  
(Schindler et al 1995, Lanteri et al 1995,Yossef-Ahmed et al 1996). However, in some patients, e.g. 
those with severe left heart valvular obstruction, the cardiovascular stimulation produced by 
ketamine may be not desirable. Furthermore, the use of ketamine in patients with depleted 
endogenous catecholamine stores due to critical illness may result in impaired cardiac performance 
(Christ et al 1997). Propofol has been demonstrated to reduce systemic arterial pressure and SVR in 
patients with CHD, with no effects on cardiac rhythm (Lebovic et al 1992, Friesen et al 1996). 
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However, in children undergoing CPB propofol administration has been associated with favorable 
hemodynamic and reduced stress response  (Laycock et al 1992). Its use with opiates in 
uncomplicated postoperative pediatric cardiac patients has been devoid of significant adverse 
effects (Martin et al 1997). In patients with left-to-right shunts, propofol is well tolerated, whereas 
in patients with right-to-left shunts it may reverse shunt flow. The systemic afterload reduction 
produced by propofol may be harmful in patients with severe left heart outflow obstruction, as well 
as in patients whose Q• p depends on the balance between SVR and PVR (Williams et al 1999b). 
Midazolam causes only minor hemodynamic changes when combined with opiates in adult cardiac 
patients (Kleinschmidt et al 1997). However, midazolam boluses combined with opiate infusions 
decrease cardiac output, mixed venous blood O2 content, and V
• O2 in hemodynamically stable 
children after open-heart surgery, suggesting that midazolam infusion may be preferable especially 
in children with complex surgical correction (Shekerdemian et al 1997).  
 
Neuromuscular blockade is often induced with long-acting nondepolarizing agents in young 
children with complex CHD. Pancuronium bromide is well tolerated in these patients, and the 
increased sympathetic activity associated with its administration may be advantageous if cardiac 
output is low (Maunuksela et al 1981, Cabal et al 1985). However, residual neuromuscular blockade 
secondary to usage of long-acting agents may impair the respiratory function postoperatively 
(Buzello et al 1978, Van Oldenbeek et al 1999). Shorter-acting muscle relaxants have been used 
without significant cardiac side effects in children without cardiac defects (Brandom 2000). There 
are few studies on the effects of these agents in critically ill children with CHD. Hypotension 
secondary to histamine release by neuromuscular blocking drugs may be of disadvantage especially 
in patients who do not tolerate decrease in SVR.  The lack of vagolytic action of these agents may 
also be not desirable when used with high-dose opiates (Salmenperä et al 1983). 
 
High-dose opiates provide hemodynamic stability and suppression of metabolic and hormonal stress 
response in critically ill children (Hickey et al 1985a, Anand et al 1992, Duncan et al 2000). 
However, when combined with benzodiazepines, fentanyl and sufentanil have been demonstrated to 
provide more complete suppression of cardiovascular and hormonal responses to intense 
stimulation in children with CHD (Morgan et al 1987, Barankay et al 1992). Alfentanil has been 
used in patients in whom early extubation has been desirable. However, when administrated with 
inhaled anesthetics, alfentanil boluses may produce bradycardia in infants with CHD (den 
Hollander et al 1988).  
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2. Postoperative vasoactive support in children recovering from open-heart operations 
 
In the postoperative management of a child with complex CHD, manipulation of all determinants of 
cardiac output, namely heart rate, preload, afterload and contractility, is often required (Thys & 
Dauchot 1993). Temporary pacemakers are frequently used to provide adequate heart rate and 
atrioventricular synchrony. Low diastolic compliance in young children allows limited margin for 
volume loading to increase stroke volume (Thornburg et al 1983). Therefore, administration of 
vasoactive agents according to the underlying pathophysiology of the cardiac defect is often 
necessary. 
 
2.1. Catecholamines 
 
Dopamine is a naturally occurring immediate precursor of norepinephrine, with a variety of dose-
dependent effects on α-, β-, and dopaminergic receptors. At low doses it stimulates renal 
dopaminergic D1-and D2-receptors, resulting in vasodilatation in the coronary, renal, mesenteric, 
and cerebral circulations. This effect is mediated by increased production of cAMP by postsynaptic 
D1-receptors, and inhibition of norepinephrine release by presynaptic D2-receptors.   At moderate 
doses, dopamine exerts a dose-dependent β1-adrenergic agonist effects with resultant increase in 
heart rate, stroke volume, and cardiac output, but with little effect on peripheral arterial resistance.  
At high doses α1-adrenergic effects increase systemic arterial and venous pressures, left ventricular 
filling pressures, and decrease mesenteric and renal blood flow. Increased myocardial V• O2, 
arrhythmias, suppression in insulin secretion and accelerated glucose production may be associated 
with dopamine administration especially at high doses  (Notterman 1991, Seri 1995). 
 
The dose of dopamine necessary for adequate inotropic support varies with age. Neonates and 
infants require higher doses of dopamine to achieve significant increase in cardiac output than older 
children or adult patients after cardiac surgery. Fortunately, the same age-dependency holds true for 
adverse side effects as well (Perez et al 1986, Outwater et al 1990, Bhatt-Mehta et al 1991). This 
variation may be secondary to differences in the sympathetic innervation of the heart and peripheral 
tissues, cardiac catecholamine stores, compliance of the myocardium, and dopamine 
pharmacokinetics (Friedman 1972, Erath et al 1982, Steinberg et al 1994). Dopamine has been 
suggested to act as a pulmonary vasoconstrictor in children with pulmonary vascular obstructive 
disease undergoing cardiac catheterization, as well as in infants after CPB (Driscoll et al 1979, 
Booker et al 1995). However, in contrast to these results, not even high doses of dopamine affected 
pulmonary vascular tone adversely in some children with CHD (Outwater et al 1990). This could 
possibly be explained by differences in the pre-existing pulmonary hypertension despite similar 
surgical procedures.  In infants and children with CHD, dopamine increases renal blood flow and 
glomerular filtration rate independently from increase of cardiac output (Girardin et al 1989, 
Outwater et al 1990). In addition to the specific effects of dopamine on renal function, its 
administration has been suggested to increase liver blood flow postoperatively in children with 
CHD (Mitchell et al 1995).  Dopamine is frequently used in patients with TGA and AVSD for 
postoperative inotropic support (Wernovsky et al 1995a, Bando et al 1995, Bando et al 1996).  
Dopamine pharmacokinetics in children are outlined in Table 1. 
 
Dobutamine, a synthetic catecholamine, is β1-selective, and has a low affinity for β2-    -
receptors (Zaritsky et al 1984).  Dobutamine has no dopaminergic effects and does not stimulate the 
release of endogenous catecholamines (Tuttle et al 1975). In critically ill children, an improvement 
in the systolic cardiac function and increase in heart rate has been shown even when small doses are 
used. However, plasma dobutamine concentration necessary to initiate hemodynamic responses 
varies widely (Berg et al 1993). When compared with dopamine in young children undergoing 
cardiac surgery, similar hemodynamic actions of the two drugs have been demonstrated in a 
blinded, double crossover study. However, dopamine increased PAP and PVR significantly in high 
doses probably 	
 	   -adrenergic receptor effect (Booker et al 1995). Dopamine is not 
superior to dobutamine for protection of renal function in children after CPB (Wenstone et al 1991). 
The pharmacokinetic data of dobutamine in children are presented in Table 1. 
 

  
 	

 	   -, β1- and β2 -adrenergic effects.  At low 
doses, myocardial contractility increases and SVR decreases secondary to effects on β-receptors. 
	
   	 
   - adrenergic effects become predominant, leading to increased 
peripheral resistance to blood flow. At high doses, myocardial irritability and arrhythmias may 
occur. Increased heart rate and contractility may affect myocardial V• O2 adversely (Notterman 
1991). Furthermore, epinephrine administration may impair splanchnic perfusion in situations when 
the regional O2 balance is compromised (Meier-Hellmann et al 1997). Epinephrine has a significant 
calorigenic response; it stimulates lipolysis, and accelerates glycogenolysis, and gluconeogenesis, 
leading to production of lactate. Epinephrine administration also is associated with a decrease in  
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serum potassium levels (Sjöström et al 1983, Macdonald et al 1985). Epinephrine infusions are 
often used in children with pulmonary hypertension undergoing reconstructive surgery for further 
inotropic support (Bando et al 1996).  Pharmacokinetic data of epinephrine in children are presented 
in Table 1. 
 
Norepinephrine, like epinephrine, is a naturally occurring cat 	  		  -
adrenergic action, though some β1-adrenergic effects have been demonstrated.  Administration of 
norepinephrine results in arteriolar constriction in many vascular beds. Additionally, like 
epinephrine, norepinephrine increases preload secondary to venous constriction.  Increase in SVR 
and blood pressure often leads to vagal reflex slowing of heart rate. Cardiac output either remains 
unchanged or decreases slightly (Zaritsky et al 1984). Increase in PVR and splanchnic and renal 
vasoconstriction also have been shown to result from norepinephrine administration. The metabolic 
effects of norepinephrine are similar to epinephrine (Notterman 1991). Pharmacokinetic data of 
norepinephrine in children is limited (Table 1). 
 
Isoprenaline is a synthetic derivative of norepinephrine with nonspecific β-adrenergic agonist 
activity.  The principal therapeutic effects associated with isoprenaline are chronotropic and 
inotropic, peripheral vasodilatation augmenting the chronotropic action, pulmonary vasodilatation, 
and bronchial smooth muscle relaxation.  Isoprenaline is used for the treatment of bradycardia, 
reactive pulmonary hypertension and status asthmaticus (Steinberg et al 1994).  However, decreased 
diastolic blood pressure and shortened diastole during tachycardia may impair myocardial O2 
delivery (Matson et al 1978), an effect especially undesirable in children with abnormal coronary 
vasculature.  Ventricular and atrial tachyarrhythmias, and increase in intrapulmonary shunting also 
may occur (Notterman 1991). Pharmacokinetics of isoprenaline in children are presented in Table 1. 
 
Dopexamine, a synthetic catecholamine, is regarded mainly as an agonist at the D1-, D2- , and β2 -
receptors, while β1 -adrenoceptor effects are considered weak  (Brodde 1988). Its sympathomimetic 
action is indirect, secondary to inhibition of uptake1(neuronal tissue uptake of norepinephrine) and 
potentiation of endogenous noradrenaline effects (Mitchell et al 1987, Napoleone et al 1992). 
Dopaminergic and indirect sympathomimetic actions appear to predominate at low doses (Geisser et 
al 1997). An increase in arterial pressure, arterial pH and urine output have been associated with 
dopexamine administration in critically ill neonates (Kawczynski et al 1996). In older children after 
surgery for CHD, dopexamine increased cardiac index and heart rate significantly, while no 
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significant effect on stroke volume index and PVR could be shown. Decrease in SVR was observed 
only at high doses of dopexamine, suggesting predominantly β1-adrenoceptor activation (Habre et 
al 1996). These results differ from studies in adult cardiac patients in whom the decrease in SVR 
has been proposed as the main action of dopexamine  (Stephan et al 1990, Sherry et al 1997). This 
discrepancy may be due to variation in the extent of the β-adrenoceptor downregulation in the 
different patient groups under study.  The effects of dopexamine on renal function are controversial. 
Even though improved creatinine CL following dopexamine administration has been shown in 
adults after cardiac surgery, no renal vascular vasodilation could be demonstrated in pediatric 
patients (Habre et al 1996, Berendes et al 1997). Furthermore, postoperative increase in renal 
vascular resistance occurs to a similar extent in both dopexamine and placebo groups in adults 
(Sherry et al 1997). Dopexamine administration reduces the gastrointestinal tract permeability 
following CPB, and attenuates the endotoxin-mediated increase in cytokine levels (Sinclair et al 
1997, Berendes et al 1997). When administered to infants undergoing CPB, it increases gastric 
mucosal perfusion after rewarming from profound hypothermia (Booker et al 2000). In noncardiac 
surgical adult patients under mechanical ventilation dopexamine administration has not resulted in 
impairment of pulmonary gas exchange (Hachenberg et al 1998). However, no reports on 
pulmonary effects of dopexamine in children undergoing cardiac surgery are available.  
Pharmacokinetic data on dopexamine in children have not been published so far (Table 1). 
 
2.2. Vasodilators 
 
Vasoconstriction secondary to increased sympathetic activity associated with heart failure increases 
the cardiac afterload (Ross et al 1987, Thys & Dauchot 1993). Reduction of ventricular workload 
postoperatively is important especially in neonates and infants, as their limited cardiac performance 
is further compromised by surgery and CPB.  Several different intravenous vasodilators have been 
used to manipulate afterload in children after cardiac surgery. Administration of sodium 
nitroprusside and nitroglycerine provide vasodilation by releasing intracellular NO that activates 
soluble guanylate cyclase and increases the production of cyclic guanosine monophosphate (cGMP) 
(Gruetter et al 1981, Moncada et al 1991). Basal release of endogenous NO in both systemic and 
pulmonary circulations appears to lead to constant inhibition of smooth muscle contraction (Rees et 
al 1989). In patients with left ventricle dysfunction, sodium nitroprusside has been shown to dilate 
mainly arterial resistance vessels, even though venous capacitance vessels are also affected. 
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 Table 1. Pharmacokinetic parameters of different catecholamines in children. 
Catecholamine CL (ml/kg/min) Vd (l/kg) T
½
 (minutes) Metabolism route 
Dopamine 115 in neonates and infants 
(Bhatt-Mehta et al 1991) 
83 ± 28 in children < 2 years 
(Notterman et al 1990) 
46 ± 17 in children > 2 years 
(Notterman et al 1990) 
1.8 in neonates 
and infants 
(Bhatt-Mehta et al 
1991) 
7 in neonates and 
infants (Bhatt-Mehta 
et al 1991) 
Liver, kidneys, 
pulmonary endothelium 
(Seri 1995) 
Methylation, 
deamination or 
conjugation to sulphate 
(Steinberg et al 1994) 
 
Dobutamine 82 ± 3 (Berg et al 1993) 0.07-5.64 
(Schwartz et al 
1991) 
-phase: 1.7 ± 0.2 
-phase: 26 ± 12 
(Schwartz et al 1991)  
Liver, kidneys  
Methylation, 
glucuronidation  
Uptake2 
(Steinberg et al 1994) 
Isoprenaline 43 ± 5 (Reyes et al 1993)  0.22 ± 0.06 
(Reyes et al 1993) 
4.2 ± 1.5 
 (Reyes et al 1993) 
Liver, kidneys 
Methylation 
Uptake2 
(Steinberg et al 1994) 
Epinephrine 29 ± 16 (Fisher et al 1993) Not reported -phase: 2  
(Steinberg et al 1994) 
Liver, kidneys  
Methylation, 
deamination 
Uptake2 
(Steinberg et al 1994) 
Norepinephrine Not reported Not reported 2-2.5 
(Steinberg et al 1994) 
Liver, kidneys  
Methylation, 
deamination  
Uptake1 and uptake 2  
(Steinberg et al 1994) 
Dopexamine Not reported Not reported Not reported Not reported 
Values are given as mean ± standard deviation, mean, or range. 
Abbreviations: CL, clearance; Vd, volume of distribution; T
½,
 elimination half-life. 
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Nitroglycerin has a predominant effect on venous capacitance vessels, but some arterial vasodilative 
effects can be seen as well (Kirsten et al 1998). These drugs improve cardiac performance in 
children with CHD, especially when combined with inotropic agents (Benzing et al 1979, Bando et 
al 1996). In patients with CHD, sodium nitroprusside has been demonstrated to reduce complement 
activation during CPB (Seghaye et al 1996).  Methemoglobinemia and production of cyanide may 
lead to tissue anoxia when sodium nitroprusside is administrated in high doses (Ivankovich et al 
1983). The elimination half-life (T½) of sodium nitroprusside is 3-4 minutes in adults (Weir et al 
1989). Nitroglycerine concentration declines rapidly after cessation of administration because of 
vascular metabolism. The CL of nitroglycerine, also affected by cardiac output, is 0.3-1.0 l/kg/min, 
the plasma half-life is 2.8 ± 0.9 minutes, and the Vd is 3 l/kg in adults (McNiff et al 1981, Fung 
1987). The pharmacokinetics of nitrosovasodilators have not been well characterized in children 
with CHD (Table 2). However, it has been suggested that there are no significant aberrations from 
adult pharmacokinetics during pediatric use (Kirsten et al 1998). 
 
Intravenous prostaglandin E1 (PGE1), and PGI2 have been used to improve postoperative cardiac 
performance in patients with right heart failure (D´Ambra et al 1985). However, the vasodilating 
effect of intravenous prostaglandins on systemic vasculature may limit their use in critically ill 
children during the postoperative period (Turanlahti et al 1998). Long-term administration is well 
tolerated in children with pulmonary hypertension who fail conventional therapy (Rosenzweig et al 
1999). In adults, the CL of PGE1and PGI2 is 20 ml/kg/min, and the Vd is 0.8 l/kg (Kirsten et al 
1998).  The terminal half-life of PGE1 -	 ! -phase 8.2 ± 6.3 
minutes (Cawello et al 1994).  The disposition of PGI2 after discontinuation of infusion is biphasic 
with half-lives of 3 and 30 minutes in adults (Kirsten et al 1998). The pharmacokinetics of the 
PGE1 and PGI2 have not been established in critically ill children with CHD (Table 2). 
 
Hypotension, increase in intrapulmonary shunting from attenuated hypoxic pulmonary 
vasoconstriction, and reduced PaO2 may follow nitrate administration (Mookherjee et al 1978, 
Radermacher et al 1989). Different intravenous vasodilators have been used in the management of 
children with pulmonary hypertension associated with CHD, even though the lack of selectivity on 
pulmonary circulation may limit their use in these patients (Houde et al 1993).  
 
Inhaled exogenous NO provides selective vasodilation of pulmonary arteries, improvement in 
arterial oxygenation, and right ventricular performance postoperatively in children with pulmonary 
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hypertension and after Fontan-type repair of CHD (Miller et al 1994a, Journois et al 1994b, 
Goldman et al 1995, Schulze-Neick et al 1997). However, in controlled randomized trials inhaled 
NO has offered little advantage over conventional therapy in patients with increased pulmonary 
artery pressure postoperatively (Russell et al 1998, Day et al 2000). These findings may be affected 
by the patient entry criteria, the underlying cardiac pathophysiology, conventional therapy used, as 
well as the NO doses used in these studies.  Preoperatively, NO has been used to test the 
reversibility of pulmonary hypertension (Roberts et al 1993, Winberg et al 1994, Berner et al 1996, 
Turanlahti et al 1998). Since NO is rapidly inactivated by binding to hemoglobin, its vasodilatory 
effect seems to be restricted to the pulmonary vasculature without significant systemic action 
(Frostell et al 1993). However, NO bound to hemoglobin may have a prolonged effect on systemic 
circulation secondary to formation of S-nitrosothiols (Jia et al 1996).  Pulmonary edema may occur 
during NO therapy in patients with severe left ventricular failure, probably secondary to increase in 
pulmonary venous return  (Bocchi et al 1994).  The antithrombotic effect of NO has been suggested 
in adults with adult respiratory distress syndrome, but the significance of this finding has not been 
confirmed in children with CHD (Samama et al 1995). Determination of the lowest effective dose 
of NO is important, because a combination of NO and high FIO2 leads rapidly to production of 
toxic nitric dioxide (NO2), and the inactivation of NO may lead to methemoglobinemia especially 
in neonates with immature methemoglobin reductase activity (Foubert et al 1992, Miller et al 
1994b, Mansouri et al 1993). The use of very low-dose inhaled NO has been shown to be effective 
in some patients with postoperative pulmonary hypertension (Miller et al 1994a, Beghetti et al 
1995). 
 
The alternative use of inhaled PGI2 has been proposed for postoperative pulmonary hypertension, 
but the local adverse effects of this agent, as well as its effects on platelet function, during 
prolonged administration in critically ill children are unknown (Zwissler et al 1995, Pappert et al 
1995, Haraldsson et al 1996, Forrest et al 1999). 
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Table 2. Pharmacokinetics of intravenous vasodilators in children. 
Vasodilator CL (ml/kg/min) Vd (l/kg) T
½
 (minutes) Metabolism route 
Nitroprusside Not reported Not reported Not reported Kidneys 
Degradation to cyanide 
and detoxification to 
thiocyanate (Kirsten et 
al 1998) 
Nitroglycerine Not reported Not reported Not reported Liver 
Arteriovenous 
extraction, vascular 
metabolism (Fung 
1987, McNiff et al 
1981) 
Prostacyclin Not reported Not reported Not reported Liver and kidneys 
(Kirsten et al 1998) 
Prostaglandin E1 Not reported Not reported Not reported Lungs and liver 
(Kirsten et al 1998) 
Abbreviations: CL, clearance; Vd, volume of distribution; T
½
, elimination half-life. 
 
 
2.3. Phosphodiesterase inhibitors 
 
Phosphodiesterase inhibitors are non-glycoside, non-sympathomimetic drugs, with a competitive 
inhibitory action on the PDE isoenzyme III.  They increase intracellular cAMP levels in myocytes 
and vascular smooth muscle cells by inhibiting the hydrolysis of cAMP, which leads to increased 
inotropy, peripheral vasodilatation, and enhanced myocardial relaxation (Honerjäger 1991, Skoyles 
et al 1992). Unlike catecholamines, PDE inhibitors have been shown to improve myocardial 
performance without raising myocardial V• O2  or increasing afterload (Benotti et al 1980, Sakaki et 
al 1998).  They do not appear to be accompanied by the β-receptor desensitization and 
downregulation, but may shift the β1- to β2- adrenoceptor ratio toward β2- adrenoceptors (Feldman 
et al 1990).   Evidence is also available that the PDE activity is not altered in human heart failure 
(De Mello 1996). The ability of β-adrenergic agonists to stimulate adenylate cyclase is decreased in 
neonates, probably due to uncoupling of β-adrenoceptors and adenylate cyclase activity at early age 
(Baum et al 1997). However, age does not affect the PDE inhibitor effect (Foged et al 1990). 
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Amrinone and milrinone are bipyridine derivatives, whereas enoximone and piroximone are 
imidazole derivatives providing selective PDE III inhibition (Skoyles et al 1992). 
 
In neonatal piglet hearts, negative inotropic effects from amrinone administration have been 
observed (Ross-Ascuitto et al 1989). In pediatric patients after cardiac surgery, amrinone increases 
cardiac output and decreases SVR (Lynn et al 1993, Sorensen et al 1996). Amrinone has been 
suggested to act mainly as a systemic vasodilator without significant inotropic effect (Berner et al 
1990). However, when compared with sodium nitroprusside, amrinone provides a significantly 
larger increase in cardiac output per unit decrease in blood pressure (Bailey et al 1997). This 
discrepancy may be explained by differences in the dosing regimen, volume loading to provide 
stable preload, and the baseline condition of the patients in these studies. Administration of 
amrinone has resulted in reduction of high PVR in children undergoing cardiac catheterization as 
well as after cardiac surgery (Wessel et al 1989, Robinson et al 1993). Additive effects have been 
demonstrated when catecholamines are administered concomitantly with amrinone in adults after 
CPB (Royster et al 1993). The dosing recommendations established to achieve therapeutic serum 
concentrations in adults have resulted in wide range of serum amrinone levels in children, all with 
acceptable cardiac performance (Edelson et al 1981, Allen-Webb et al 1994). The relationship 
between amrinone concentration and hemodynamic response is unknown in children undergoing 
cardiac surgery for CHD. Refractory hypotension has been reported to follow amrinone overdosing 
(Lebovitz et al 1995).  Peritoneal dialysis is ineffective in treatment of toxic amrinone overdose 
(Lawless et al 1993). The pharmacokinetics of amrinone in children have been previously studied in 
heterogeneous patient populations (Lawless et al 1989, Allen-Web et al 1994).  In adults amrinone 
CL is affected by acetylator phenotype; in slow acetylators it is approximately 50 % of that in fast 
acetylators (Hamilton et al 1987).  Increased incidence of slow acetylation has been observed in 
young children (Szorady et al 1987, Pariente-Khayat et al 1991). However, in children from 1 to 
160 months of age no age-related differences in amrinone elimination have been observed (Allen-
Web et al 1994).  There is little information on amrinone pharmacokinetics in neonates during the 
first four weeks of life (Lawless et al 1989, Allen-Web et al 1994, Williams et al 1995).  The 
pharmacokinetic data of amrinone in children are presented in Table 3. 
 
Milrinone lowers filling pressures, SVR, and PVR, while improving cardiac index in neonates after 
cardiac surgery as well as in pediatric patients with septic shock  (Chang et al 1995, Lindsay et al 
1998). Milrinone, similarly to amrinone, increases the inotropic state of the myocardium, when 
compared to nitroprusside for a matched reduction in mean aortic pressure or SVR in patients with 
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heart failure (Jaski et al 1985). Milrinone administration has resulted in reduced endotoxin and 
interleukin levels in adults undergoing CPB when compared with placebo, but it does not confer 
protection against splanchnic ischemia over dopamine (Mollhoff et al 1999, McNicol et al 1999). 
Moreover, the higher amount of colloids given before CPB in the milrinone-treated group when 
compared to placebo group may have contributed to the observed effects. The pharmacokinetics of 
milrinone in children are presented in Table 3. 
 
The administration of enoximone improved cardiac performance in neonates and infants with 
postoperative low-output states refractory to high-dose catecholamine therapy.  A transient fall in 
systemic arterial pressure, responding to volume loading, was observed during enoximone therapy; 
no bleeding disturbances or arrhythmias were noted (Schranz et al 1989, Hausdorf 1993). However, 
enoximone did not provide advantage in inotropic and vasodilating effects over a combination of 
dobutamine and phenoxybenzamine in children with tetralogy of Fallot and AVSD. This result may 
have been confounded by the low loading dose of enoximone administered during the CPB (Innes 
et al 1994). Improvement in O2 delivery associated with enoximone did not prevent gastric mucosal 
acidosis even though endotoxin levels were significantly diminished in adults after CPB  (Loick et 
al 1997). No studies on enoximone pharmacokinetics are available in children. Piroximone has been 
successfully used to increase cardiac index and decrease SVR in adult cardiac surgical patients 
(Hausen et al 1992), but no studies on its administration on pediatric patients have been published 
so far. The T½ of enoximone is 4.3 hours, and that of piroximone is 1.3 ± 0.2 hours in adults 
(Skoyles et al 1992, Fauvel at al 1995). 
 
Thrombocytopenia has been associated with amrinone administration secondary to nonimmune-
mediated peripheral platelet destruction, decreased platelet survival time and increased numbers of 
megathrombocytes. Exposure to N-acetylamrinone, the primary metabolite of amrinone, has been 
suggested to be toxic to platelets especially in patients with rapid acetylator phenotype (Ross et al 
1993). However, no hemorrhagic complications have been reported with short-term administration 
of PDE inhibitors in pediatric patients (Berner et al 1990, Lynn et al 1993). In adult cardiac patients, 
milrinone, enoximone, and piroximone administration do not cause significant changes in platelet 
number or function during the first 24 postoperative hours beyond the usual effects of cardiac 
surgery and CPB (Boldt et al 1992, Kikura et al 1995).  However, in infants and children receiving 
milrinone after cardiac surgery, thrombocytopenia occurred in 58 % of the patients, and the risk 
increased with duration of the infusion (Ramamoorthy et al 1998). This difference may be 
explained by the shorter observation time in adult patients. 
 
Table 3. Pharmacokinetic data of PDE III inhibitors in children. 
PDE III inhibitor CL (ml/kg/min) Vd (l/kg) T
½
 (hours) Metabolism route 
Amrinone 2.9 ± 1.7 in neonates 
and infants (Lawless 
et al 1989) 
2.2 ± 0.9 in children 
(Sorensen et al 1996) 
2.5 ± 1.5 in children 
(Allen- Webb 1994) 
1.7 in children < 1 
year (Lawless et al 
1989) 
1.0 ± 0.4 in children 
(Allen-Webb et al 
1994) 
12.7-15.6 in neonates 
3.8-6.4 in infants 
(Lawless et al 1989) 
5.5 ± 2.3 in children 
(Allen-Webb et al 
1994) 
Liver, kidneys 
Acetylation, 
glucuronidation, 
glutathione addition 
(Steinberg et al 1994) 
Milrinone 3.8 in infants 
5.9 in children 
(Ramamoorthy et al 
1998) 
0.9 in infants 
0.7 in children 
(Ramamoorthy et al 
1998) 
1.5 ± 1.0  
(Lindsay et al 1998) 
0.6-10.9, mean 1.5 
(Lindsay et al 1998) 
Mainly by kidneys 
(Skoyles et al 1992) 
Enoximone Not reported Not reported Not reported Mainly by liver 
Sulphoxidation 
(Skoyles et al 1992) 
Piroximone Not reported Not reported Not reported Kidneys (Fauvel et al 
1995) 
Values are given as mean ± standard deviation, mean, or range.  
Abbreviations: CL, clearance; Vd, volume of distribution; T
½
, elimination half-life. 
 
3. Summary of the literature review 
 
In summary, lesions with increased Q• p, such as AVSD, are associated with volume overload of the 
heart, and volume or pressure overload of the pulmonary circulation that predispose the patients to 
extension of distal muscularization in pulmonary arteries and increased PVR (Newfeld et al 1977, 
Young 1980). Even when reconstructive surgery is performed in early infancy, pulmonary 
hypertensive events may complicate the recovery of these patients (Hopkins et al 1991, Bando et al 
1995). In neonates with TGA, the left ventricle loses its capacity to grow and overcome high 
afterload as the PVR decreases within the first weeks of life. In these patients, however, the 
gradually increasing PVR predisposes the child to pulmonary vascular obstructive disease and 
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increased risks of surgery. Therefore, the correct timing of reconstructive surgery is essential for the 
successful correction of these defects (Bano-Rodrigo et al 1980, Bush et al 1988, Bando et al 1996).  
 
Precise determination of cardiac output is required when the hemodynamic status of the patient and 
the actual vasodilator capacity of the pulmonary vascular bed are assessed preoperatively. The 
determination of Q• s and Q• p using the Fick principle depends on quantitation of CavO2 across the 
vascular bed, and V• O2. The use of indirect calorimetry to determine V
• O2 and V
• CO2, resulting 
from measurements of the inspired and expired O2 and CO2 concentrations and the volume of 
expired gas, may be sometimes cumbersome during mechanical ventilation and when high FIO2 are 
needed (Nunn et al 1989, Takala et al 1989, Weyland et al 1993). The V• O2 measurement may be 
especially difficult in children with CHD, so the V• O2 values are often estimated from nomograms 
constructed according to the patient’s characteristics (Wessel et al 1969, LaFarge et al 1970, 
Lindahl 1989). The use of linear methods in estimation of the V• O2 has been shown to result in wide 
CI of the calculated values (Lundell et al 1996, Sherman et al 1997). Furthermore, the linear 
regression equations predicting V• O2 are usually based on data obtained from stable subjects 
undergoing cardiac catheterization, and are not easily applied to different patient populations in 
other clinical situations. There are no studies in which nonlinear artificial intelligence NN has been 
used to improve the predictive accuracy of the regression equations (Cross et al 1995). 
 
The patients with AVSD and TGA are prone to low cardiac output and increased vascular 
resistances during the early postoperative period secondary to the combined effects of underlying 
cardiac pathophysiology, anesthetic management, surgery itself, and use of CPB  (Kirklin et al 
1981, Anand et al 1992, Wernovsky et al 1995a, Bando et al 1996, Royston 1997). Children with 
CHD have increased sympathetic activity.  Secondary to this elevated tone, these patients present 
down-regulation and uncoupling of the myocardial and lymphocyte β-adrenoceptors (Ross et al 
1987, Kozlik-Friedman et al 1993, Dzimiri et al 1995, Wu et al 1996). Especially low β-
adrenoceptor densities have been found in neonates with aortic stenosis and TGA. In these patients, 
additional significant β2-adrenoceptor down-regulation may be present (Kozlik-Friedman et al 
1993). Therefore, the efficacy of β1- as well as β2-adrenoceptor agonists may be limited in these 
patients (Feldman et al 1990, Brodde 1991). 
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Even though the cardiac surgical procedure itself often improves cardiac output, the intraoperative 
myocardial damage may decrease it during the early postoperative period. It may be the result of 
incomplete operation, and several mechanical problems (Kirklin & Barrat-Boyes 1993). In patients 
with AVSD, restoration of a competent left-sided atrioventricular valve, and elimination of residual 
intracardiac communications are critical to the outcome (Bando et al 1995). In patients with TGA, 
adequate coronary blood flow after transfer of the coronary arteries to the neoaorta without 
narrowing or distortion is required for a successful arterial switch operation. Unusual coronary 
anatomy predisposes these patients for complicated postoperative course (Wernovsky et al 1995b).  
 
Pronounced inflammatory response is associated with cardiac surgery and CPB. The myocardium, 
pulmonary system, splanchnic bed and kidneys are important targets that contribute to the 
postoperative course after cardiac surgery. Tissue ischemia, hypothermia, relative hypotension 
during nonpulsative flow, hemodilution, and administration of blood products and pharmacological 
agents may affect the inflammatory response (Royston 1997). Despite interindividual variation in 
the response to the inflammation during CPB, neonates and infants, and patients who require long 
CPB times, are especially at risk to systemic effects of endothelial injury (Kirklin et al 1983). The 
use of hypothermia during CPB increases myocardial tolerance to the ischemia associated with 
aortic cross-clamp and cardioplegia. Reduction of myocardial O2 demand by using total CPB, 
diastolic arrest, venting of the heart, and controlled reperfusion decreases the mismatch between 
myocardial O2 supply and demand  (Senning 1952, Buckberg et al 1977,Vinten-Johansen & 
Hammond 1993, Gates, Cushen & Laks 1993). However, the use of hypothermia does not prevent 
the neutrophil-endothelial cell adhesion even though it is delayed (De Leist et al 1995). 
Hemofiltration and the use of leukocyte-depleted blood may decrease plasma levels of complement 
components and cytokines, and prevent reperfusion injury in pediatric patients (Breda et al 1989, 
Journois et al 1994a, Hayashi et al 2000). 
 
Hormonal and metabolic stress responses to cardiac surgery and CPB correlate with postoperative 
morbidity and mortality in neonates despite hemodynamic stability (Anand et al 1990, Anand et al 
1992). The extension of anesthetic period postoperatively and ventilatory control to avoid 
hypoventilation and acidosis have been associated with reduced postoperative morbidity in high-
risk patients (Hopkins et al 1991, Wernovsky et al 1995a, Wernovsky et al 1995b, Bando et al 
1996). High-dose opiates provide hemodynamic stability and suppression of metabolic and 
hormonal stress response in critically ill children (Hickey et al 1985a, Anand et al 1992, Duncan et 
al 2000). When combined with benzodiazepines, opiates provide more complete suppression of 
cardiovascular and hormonal responses to intense stimulation in children with CHD (Morgan et al 
1987, Barankay et al 1992). Midazolam infusion is preferable in children with complex surgical 
correction receiving also opiates (Shekerdemian et al 1997). Pancuronium bromide is well tolerated 
in these patients, and the increased sympathetic activity associated with its administration may be 
advantageous if cardiac output is low (Maunuksela et al 1981, Cabal et al 1985).  
 
Secondary to the above mentioned pre- and perioperative effects administration of vasoactive 
support is often necessary postoperatively.  Dopamine, epinephrine and nitroglycerine are 
frequently used in inotropic support in these patients (Wernovsky et al 1995a, Bando et al 1996). 
Neonates and infants need higher doses of dopamine to achieve significant increase in cardiac 
output than older children or adult patients after cardiac surgery (Perez et al 1986, Outwater et al 
1990, Bhatt-Mehta et al 1991). Dopamine has been suggested to act as a pulmonary vasoconstrictor 
in children with pulmonary vascular obstructive disease undergoing cardiac catheterization, as well 
as in infants after CPB (Driscoll et al 1979, Booker et al 1995). However, not even high doses of 
dopamine affected pulmonary vascular tone adversely in some children with CHD (Outwater et al 
1990). At low epinephrine doses, myocardial contractility increases and SVR decreases secondary 
to effects on β-  
        -adrenergic effects become 
predominant, leading to increased peripheral resistance to blood flow. At high doses, myocardial 
irritability and arrhythmias may occur. Increased heart rate and contractility may affect myocardial 
V• O2 adversely (Notterman 1991). Epinephrine administration may also impair splanchnic perfusion 
in situations when the regional O2 balance is compromised (Meier-Hellmann et al 1997). 
 
Reduction of the increased ventricular workload postoperatively is important especially in neonates 
and infants, as their limited cardiac performance is further compromised by surgery and CPB (Ross 
et al 1987, Thys & Dauchot 1993). Administration of nitroglycerine provides vasodilation 
predominantly in venous capacitance vessels, but some arterial vasodilative effects can be seen as 
well (Kirsten et al 1998). Nitroglycerine improves cardiac performance in children with CHD, 
especially when combined with inotropic agents (Bando et al 1996). However, hypotension, 
increase in intrapulmonary shunting from attenuated hypoxic pulmonary vasoconstriction, and 
reduced PaO2 may follow nitrate administration (Mookherjee et al 1978, Radermacher et al 1989). 
Lack of selectivity on pulmonary circulation may sometimes limit the use of intravenous 
vasodilators in patients with reactive pulmonary vasculature (Houde et al 1993). 
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Unlike catecholamines, PDE inhibitors have been shown to improve myocardial performance 
without raising myocardial V• O2 or increasing afterload (Benotti et al 1980, Sakaki et al 1998). 
They do not appear to be accompanied by the β-receptor desensitization and downregulation, but 
may shift the β1- to β2- adrenoceptor ratio toward β2- adrenoceptors (Feldman et al 1990).  In 
patients with CHD, especially in neonates with TGA, drugs augmenting β-adrenergic stimuli 
beyond the receptor level, such as PDE inhibitors, can be useful in postoperative cardiovascular 
support (Feldman et al 1990, Brodde 1991, Kozlik-Friedman et al 1993). In children after cardiac 
surgery, amrinone increases cardiac output and decreases SVR (Lynn et al 1993, Sorensen et al 
1996). It has been suggested to act mainly as a systemic vasodilator without significant inotropic 
effect (Berner et al 1990). However, amrinone provides a significantly larger increase in cardiac 
output per unit decrease in blood pressure when it is compared with sodium nitroprusside (Bailey et 
al 1997). Administration of amrinone has resulted in reduction of high PVR in children undergoing 
cardiac catheterization and after cardiac surgery (Wessel et al 1989, Robinson et al 1993). Additive 
effects have been demonstrated when catecholamines are administered concomitantly with 
amrinone in adults after CPB (Royster et al 1993). The decrease in peripheral vascular resistances 
produced by amrinone often necessitates preload augmentation to avoid systemic hypotension, 
especially as amrinone is relatively long acting (Lawless et al 1989, Lebovitz et al 1995). 
Development of thrombocytopenia has been associated with PDE inhibitor administration (Ross et 
al 1993). However, no hemorrhagic complications have been reported with short-term 
administration of amrinone in pediatric patients so far (Berner et al 1990, Lynn et al 1993).  
 
The pharmacokinetics of amrinone in children have been previously studied in heterogeneous 
patient populations (Lawless et al 1989, Allen-Web et al 1994). In children from 1 to 160 months of 
age no age-related differences in amrinone elimination have been observed (Allen-Web et al 1994).  
There is little information on amrinone pharmacokinetics in neonates during the first four weeks of 
life (Lawless et al 1989, Allen-Web et al 1994, Williams et al 1995). 
 
 
 
 
 
 
 
 39 
 
 
AIMS OF THE PRESENT STUDY 
 
The purpose of this work was to evaluate cardiovascular management in children undergoing open-
heart surgery. The specific aims were in detail as follows: 
 
1. To evaluate the utility of the linear regression equations and the artificial intelligence NN in V• O2 
prediction by comparing measured and predicted V• O2 at preoperative cardiac catheterization in a 
group of children with CHD (I). 
 
2. To examine pharmacokinetics of amrinone in neonates and infants after open-heart surgery for 
CHD (II). 
 
3. To assess the efficacy and safety of amrinone and a combination of dopamine and nitroglycerine 
in neonates after arterial switch operation for TGA, and in infants after reconstructive surgery for 
complete AVSD, during the first 18 postoperative hours in the intensive care unit (ICU) (III, IV).  
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MATERIALS AND METHODS 
 
This study was conducted at the Hospital for Children and Adolescents, University of Helsinki, 
Finland, with the approval of the institutional Ethics Committee. Parental written informed consent 
was obtained from the patients in the prospective studies. 
 
1. Patients and study designs  
 
A total of 221 patients with CHD were enrolled in studies I-IV. In study I, 125 children with 
various CHD undergoing preoperative cardiac catheterization were studied.  In study II, 29 neonates 
and infants receiving amrinone medication after reconstructive surgery for TGA or AVSD were 
included. Thirty-five neonates with TGA, scheduled for arterial switch operation, participated in 
study III.  In study IV, 32 infants scheduled for elective repair of AVSD were enrolled. The patients 
in study II were a subgroup of patients in papers III and IV. Three patients in study I were also 
enrolled in study IV. Study I excluded patients with weight greater than 25 kg or FIO2 above 0.60.  
In studies III and IV, patients with residual left-to-right shunts, or with hemodynamic difficulties 
requiring out-of-protocol treatment were excluded. The measurements during FIO2 of 0.85 or 
higher or during NO therapy were also excluded in studies III and IV.  The study designs are 
presented in Table 4. 
 
2. Anesthetic management  (I, II, III, IV) 
 
The anesthesia was standardized in each study.  In study I, oral flunitrazepam (0.1 mg/kg, 
maximum dose 2 mg) was given as premedication.  EMLA cream (Astra, Södertälje, Sweden) was 
applied on the groins and hands of the patients before arrival to the catheterization laboratory.  
Glycopyrrolate, 5 µg/kg, was administered to all patients.  Anesthesia was induced with intravenous 
ketamine (1-5 mg/kg) and maintained with ketamine infusion (1-3 mg/kg/h).  Supplemental boluses 
of fentanyl were given as needed.  The trachea was intubated with a cuffed tube, if mechanical 
ventilation (Servo 900, Siemens, Solna, Sweden) was required.  In these patients, neuromuscular 
blockade was provided with pancuronium bromide or atracurium besylate.  The groins of 
spontaneously breathing patients were infiltrated with a local anesthetic. 
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Table 4. Study designs. 
Study Study set-up Intervention Main goal 
I Retrospective 
V
•
O2 measured with indirect calorimetry was 
compared with predicted V
•
O2 calculated according 
regression equations by Lindahl (1989), Wessel et al 
(1969) and Lundell et al (1996), and estimates 
produced with artificial NN 
To test the utility of the 
regression equations and 
NN based estimates in V
•
O2 
determination, and their 
effect on PVR calculation 
II Prospective Amrinone bolus, followed by maintenance infusion 
was given postoperatively in 15 neonates and 14 
infants 
To determine the possible 
differences in amrinone 
pharmacokinetics between 
the groups 
III Prospective, 
randomized, 
double blind 
Amrinone bolus, followed by maintenance infusion (in 
16 neonates) and a combination of dopamine and 
nitroglycerine (in 19 neonates) were compared 
postoperatively 
To assess the possible 
differences in hemodynamic 
profile, ICU and 
hospitalization times, 
adverse effects, and 
outcome between the groups 
IV Prospective, 
randomized, 
double blind 
Amrinone bolus, followed by maintenance infusion (in 
17 infants) and a combination of dopamine and 
nitroglycerine (in 15 infants) were compared 
postoperatively 
To assess the possible 
differences in hemodynamic 
profile, ICU and 
hospitalization times, 
adverse effects, and 
outcome between the groups 
Abbreviations: V
•
O2, oxygen consumption; PVR, pulmonary vascular resistance; NN, neural network; ICU, intensive 
care unit. 
 
In studies II, III, and IV, oral ketamine (10 mg/kg) was given as premedication 15 minutes before 
intravenous induction of anesthesia.   Anesthesia was induced with alfentanil 30 µg/kg and 
midazolam 300 µg/kg, and maintained with alfentanil 1-2 µg/kg/min, midazolam 1-2 µg/kg/min, 
and isoflurane.  The trachea was intubated with a cuffed tube, facilitated with pancuronium 
bromide.  Percutaneous peripheral arterial cannulation and central venous cannulation with a triple-
lumen catheter were performed after the induction of anesthesia.  Vancomycin 40 mg/kg divided 
into four daily doses, or cefuroxime 90 mg/kg divided into three daily doses were used routinely to 
prevent endocarditis. At the end of CPB, anticoagulation was reversed with protamine, 2 mg/kg, 
given slowly into a peripheral vein. After arrival in the ICU, the patients were sedated with 
continuous infusion of fentanyl, 3 µg/kg/h, while neuromuscular blockade was continued with 
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pancuronium bromide infusion, 20-30 µg/kg/h.  Supplemental fentanyl (1-2 µg/kg) and 
pancuronium (0.1 mg/kg) were given as needed.  The patients were mechanically ventilated 
(Newport Breeze, Newport Medical Instruments, Inc. Newport Beach, CA) to an arterial carbon 
dioxide tension (PaCO2) of 3.0 to 3.3 kPa and a pHa of 7.5 to 7.6 during the study period.  
Alkalemia was maintained with tris-hydroxymethylaminomethane (THAM) as needed.  Prior to 
suctioning of the airway, the patients received alfentanil 20-30 µg/kg and were manually 
hyperventilated with 100 % O2. In infants, the neuromuscular blockade was reversed and the 
patient was allowed to wake up on the first postoperative day, if recovery had been uneventful.  In 
neonates, the anesthetic period was extended to the second postoperative day. 
 
3. Surgical technique (II, III, IV) 
 
Mainly two experienced surgeons in studies II, III and IV performed the operations. 
Cardiopulmonary bypass was established with venous caval cannulas and ascending aortic cannula.  
Aortic cross-clamping was used in all patients.   In studies III and IV, the surgical technique did not 
vary between patients. In study III, the Lecompte maneuver was used in all patients, and the 
neopulmonary artery was reconstructed with a pericardial pantaloon patch.  Ventricular septal 
defect, when present, was closed with a polytetrafluoroethylene patch.  In study IV, after the duct 
closure and right atriotomy, the interventricular and interatrial communications were closed with 
polytetrafluoroethylene patches as needed. Two competent, nonstenotic atrioventricular valves were 
created by suturing the clefts in the valves.  In studies III and IV, left atrial and pulmonary artery 
catheters were inserted at surgery under direct vision. Temporary epicardial pacemaker leads and 
peritoneal dialysis catheters were also placed in all patients. Patients in study II were a subgroup of 
patients in studies III and IV. 
 
4. Management of cardiopulmonary bypass (II, III, IV) 
 
In studies II and III, and IV, CPB was conducted using a Masterflo 34, Lilliput 300, or Lilliput 400 
membrane oxygenator (Dideco, Mirandola, Italy) with priming volumes of 500 ml, 300 ml, and 400 
ml, respectively.  The circuit was primed with 4 % albumin and fresh whole blood, to achieve a 
hematocrit of 25 %.  Mannitol (150-200 mg/kg), calcium chloride (30 mg for each 100 ml of fresh 
whole blood) and heparin were added to the prime.  Deep hypothermia, 15°C in neonates and 18°C 
in infants, with intermittent cold blood cardioplegia (100 ml Plegisol, Abbot Lab., North Chicago, 
Illinois, USA, for each 100 ml of fresh whole blood, supplemented with aspartate, glutamate and 
THAM ) were used in all patients. Total circulatory arrest was used in neonates with coexisting 
aortic coarctation. All patients received a warm (37°C) blood reperfusion cardioplegia just before 
removal of the aortic cross-clamp. Hemofiltration to a hematocrit of 32 % to 42 %, and induction of 
metabolic alkalemia (pHa of 7.5 to 7.6) with THAM were performed before discontinuation of 
CPB.  
 
5. Administration of the vasoactive regimen (II, III, IV) 
 
Just before removal of the cross-clamp in studies II and III, while a warm blood reperfusion 
solution was infused via the aortic root, the patients randomized to the amrinone group were given a 
loading dose of amrinone, 2 mg/kg (Lawless et al 1989, Williams et al 1995), from a covered 
syringe into the venous reservoir of the bypass circuit. The patients randomized to the dopamine-
nitroglycerine group received the same volume of 4 % albumin, also from a covered syringe in a 
double-blind manner.  The loading dose was followed by a maintenance infusion of either amrinone 
or a combination of dopamine and nitroglycerine from a covered syringe into the covered medial 
lumen of the central venous catheter when the nasopharyngeal temperature of the patient was 
increased to 32-34 °C during the rewarming period. Amrinone, 3 mg/ml, in 0.45 % saline, was 
infused 0.15 ml/kg/h to give a dose of 7.5 µg/kg/min (Lawless et al 1989, Allen-Webb et al 1994). 
Dopamine, 200 mg, nitroglycerin, 40 mg, and 3 ml of a yellow vitamin solution (Soluvit, 
Pharmacia, Sweden), were mixed with 0.45 % saline to a total of 100 ml. This mixture, 
indistinguishable by color from the amrinone solution, was also infused 0.15 ml/kg/h to give 
dopamine 5 µg/kg/min and nitroglycerine 1 µg/kg/min (Wernovsky et al 1995b, Bando et al 1996). 
No other infusions were given through the medial lumen of the central venous catheter.  
 
Inhaled NO was administered for pulmonary vasodilation if systolic pulmonary artery pressure 
increased to more than 80 % of systolic blood pressure. An open-label epinephrine infusion into the 
proximal lumen of the central venous catheter was started according to the clinical judgment of the 
attending anesthesiologist, based on deterioration of the cardiac performance, or poor contractility 
seen with the echocardiography.  Weaning from the vasoactive medications was performed in the 
ICU also on the basis of clinical improvement in the patient’s cardiac condition, supported by 
results of echocardiography. The infusion rate of the vasoactive medications was reduced 0.1 
ml/hour in every two to four hours if no deterioration in the patient’s clinical condition was 
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observed.  Patients in study II were a subgroup of neonates and infants randomized in the amrinone 
group. 
 
6. Measurements 
 
The age, gender, weight, height and body surface area (BSA) of the patients, comorbidities, type of 
cardiac malformation and preoperative treatment for heart failure were recorded.  The decision of 
operability and outcome were recorded in patients in study I. The CPB time, aortic cross-clamp 
time, and circulatory arrest time, postoperative blood drainage volumes, need for peritoneal dialysis, 
duration of mechanical ventilation, ICU care, total hospitalization time, and outcome, were 
registered in patients in studies III and IV.  The duration of vasoactive support was recorded in 
patients in studies II, III and IV. The sampling regimens are presented in Table 5. 
 
6.1. Determination of hemodynamic parameters (I, III, IV) 
 
In studies I, III and IV an open-circuit, indirect calorimetry device (Deltatrac, Datex-Engström, 
Helsinki, Finland, or Deltatrac II, Datex-Engström, Helsinki, Finland) was used to measure V• O2. 
The calorimeter was calibrated according to the instructions supplied by the manufacturer before 
each measurement in study I and daily in studies III and IV.  The measurements were performed 
once every minute after a 10-minute stabilization period, for at least 10 minutes.  While the child 
was breathing room air spontaneously (I), a transparent canopy covered the child’s head and upper 
chest.  The expiratory gases were captured from inside the canopy by a continuous flow of gas into 
the calorimeter. Escape of expiratory gas was prevented with a soft plastic skirt attached to the rim 
of the canopy.  If supplemental O2 was used (Deltatrac II, Datex-Engström, Helsinki, Finland), the 
expiratory gases were fed through a mixing chamber (I).   During mechanical ventilation, the 
calorimeter was connected to the outlet port of the ventilator and expired gas was collected through 
a mixing chamber into the metabolic monitor (I, III, IV).  
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Table 5. Sampling regimens. 
Study Time and site of sampling  Data obtained 
I When stable conditions were achieved after induction of anesthesia: 
 
During the catheterization;  
From superior and inferior caval vein, pulmonary artery, right atrium 
and ventricle, left atrium and ventricle, and aorta (if feasible) 
 
V
•
O2 measured with indirect 
calorimetry, FIO2, heart rate 
 
Blood pressures and oxygen contents 
II After the induction of anesthesia; at 5, 10, 20, and 30 minutes after 
the loading dose (from the venous line of CPB); every 6 hours during 
the maintenance infusion; and at 2, 12, 24, and 48 hours after the end 
of the infusion (from peripheral artery)  
In patients on peritoneal dialysis, the concentrations in the dialysate 
were determined from samples taken at the time of each blood 
sample. 
Daily from the day of surgery up to fourth postoperative day;  
From peripheral artery  
 
 
Plasma and dialysate concentrations of 
amrinone, N-acetylamrinone, and N-
glycolylamrinone 
 
 
 
 
Serum creatinine and serum 
transaminase values  
 
 
III Two-hourly from 4 to 18 hours after separation from CPB; 
 
 
 
From superior caval vein, pulmonary artery, left atrium and 
peripheral artery 
Daily from the day of surgery up to fourth postoperative day;  
From peripheral artery, and from chest radiographs 
Heart rate, rhythm, rectal temperature,  
V
•
O2 measured with indirect 
calorimetry, FIO2, epinephrine dose 
 
Blood pressures and oxygen contents 
Platelet count, serum creatinine and 
serum transaminase values, positioning 
of the tracheal tube and monitoring lines  
IV Two-hourly from 4 to 18 hours after separation from CPB; 
 
 
 
From superior caval vein, pulmonary artery, left atrium and 
peripheral artery 
Daily from the day of surgery up to fourth postoperative day;  
From peripheral artery, and from chest radiographs 
 
Heart rate, rhythm, rectal temperature,  
V
•
O2 measured with indirect 
calorimetry, FIO2, epinephrine dose 
 
Blood pressures and oxygen contents 
Platelet count, serum creatinine and 
serum transaminase values, positioning 
of the tracheal tube and monitoring lines  
Abbreviations: V
•
O2, oxygen consumption; FIO2, fraction of oxygen in inspired gas; CPB, cardiopulmonary bypass. 
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In study I, the predicted V• O2 values were calculated from the following regression equations. 
According to Lindahl (1989), in children weighing < 10 kg, V• O2 (ml/min) = 6.8 × weight (kg) + 
8.0, and in those > 10 kg, V• O2 (ml/min) = 4.0 × weight (kg) + 35.8.   In the equation published by 
Wessel et al (1969), V• O2  (ml/min) = 144.8 × BSA (m2) + 5.6.  According to Lundell et al (1996), 
in children under 3 years of age, V• O2 (ml/min) = 0.40 × weight (kg) + 1.91 × height (cm) + 0.17 × 
heart rate (beat/min) - 91.0.  In males older than 3 years, V• O2 (ml/min) = 157.9 × BSA (m2) + 0.79 
× heart rate (beat/min) - 61.8.  In females older than 3 years, V• O2 (ml/min) = 159.0 × BSA (m2) + 
0.77 × heart rate (beat/min) - 61.6. 
 
For NN training and testing in study I, the data set consisting of 125 patient records was normalized 
so that all variables had values ranging from 0 to 1.  Two separate data sets were then formed using 
random selection; 101 records were selected to train the NN, while the remaining 24 records were 
used for testing the accuracy of the trained network.  A NN was first trained and tested with input 
consisting of age, gender, height, weight and heart rate, the variables used by Lundell et al (1996) to 
estimate V• O2 with linear regression.  To provide the NN with additional information to improve its 
estimate of V• O2 nine further variables were added in a second analysis to describe the patient, the 
cardiac lesion and the measurement of V• O2: BSA, V
• O2 calculated according to Lindahl´s equation 
(1989), mean pulmonary arterial pressure (PAP), mean arterial pressure (MAP), systolic 
pulmonary-to-systemic pressure ratio, cyanotic versus acyanotic nature of the cardiac malformation, 
hemoglobin concentration, presence of heart failure, and whether the V• O2 measurement was 
performed with a canopy or a ventilator.  The output requested from the NN was a number 
representing the normalized estimate of V• O2.  The absolute estimates of V
• O2 were calculated by 
reversing the normalization process.  A backpropagation NN simulated with a software package 
was used (NNmodel, Neural Fusion, Middletown, NY, USA). The NN configuration was 
determined by repeated efforts to train networks of various configurations with the training data set.  
The final network consisted of an input layer of five or 14 neurons, depending of the number of 
input variables, an intermediate layer of four neurons, and one output neuron.  Prior to training, the 
NN was initialized by setting its internal weights to random numbers.  The training data set was 
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then fed into the NN, allowing it to ‘learn’ by adjusting its internal weights after each record was 
processed, according to the difference between the estimated and true V• O2.  Observation during 
training indicated that 2000 passes of the training data set was sufficient for learning.  After 
learning was complete, the testing data set was analyzed with the network, and the resulting NN 
estimates of V• O2 were compared to the corresponding measured values.    
 
Pulmonary and systemic blood flow indexes and corresponding resistances were calculated using 
the Fick principle in studies I, III and IV as follows:  Oxygen contents were calculated as 1.36 x 
hemoglobin (g/l) x oxyhemoglobin saturation (SO2) (%) + dissolved O2.  Q• s index (l/min/m2) = V•
O2 (ml/min/m2)/arterial blood oxygen content (CaO2) - central venous blood oxygen content 
(CvO2), and Q• p index (l/min/m2) = V• O2 (ml/min/m2)/left atrial blood oxygen content (ClaO2) - 
pulmonary arterial blood oxygen content (CpaO2).  The ratio between pulmonary and systemic 
blood flows was determined as Q• p: Q• s. PVR index (Wood units x m2) = PAP - mean left atrial 
pressure (LAP)/Q• p index using both measured  (I, III, IV) and predicted (I) V• O2 values.  SVR 
index (Wood units x m2) = MAP - mean central venous pressure (CVP)/Q• s index. Oxygen 
extraction ratio (O2ER) was defined as CaO2 - CpaO2 /CaO2 (III, IV).  
 
6.2. Determination of pharmacokinetic parameters (II)  
 
Plasma was separated from the blood samples and stored at -20OC until analysis. Concentrations of 
amrinone, N-acetylamrinone, and N-glycolylamrinone were measured with high-performance liquid 
chromatography and ultraviolet detection with wavelength of 340 nm (Lawless et al 1990). WIN 
41,417 (Sanofi) was used as the internal standard. The detection limit was 0.09 µg/ml for amrinone 
and N-acetylamrinone, and 0.1 µg/ml for N-glycolylamrinone. The intra-assay coefficient of 
variation (CV) for amrinone was 3.6 % at 0.17 µg/ml and 5.7 % at 1.86 µg/ml (n =10), that for N-
acetylamrinone 5.5 % at 0.17 µg/ml and 6.1 % at 0.47 µg/ml (n =10), and that for N-
glycolylamrinone 5.8 % at 0.17 µg/ml and 5.5 % at 1.86 µg/ml (n =10). The inter-assay CV for 
amrinone was 15.1 % at 0.30 µg/ml, 7.1 % at 2.00 µg/ml, and 3.7 % at 4.99 µg/ml (n =25), that for 
N-acetylamrinone 9.7 % at 0.29 µg/ml, 6.2 % at 0.49 µg/ml, and 5.3 % at 0.99 µg/ml (n =25), and 
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that for N-glycolylamrinone 8.9 % at 0.29 µg/ml, 7.2 % at 0.50 µg/ml, and 6.5 % at 1.00 µg/ml (n 
=25).  
 
To characterize the pharmacokinetics of amrinone, its plasma CL, volume of distribution at steady-
state (V
ss
), and T½ were calculated. The CL was determined by dividing the total dose of amrinone 
by the area under the drug plasma concentration-time curve [AUC(0-]. The AUC(0- was 
calculated using the logarithmic trapezoidal rule. The elimination rate constant (k
el) was determined 
by regression analysis of the log-linear part of the curve. T½ was calculated from T½ = ln2/kel. 
Because of the small number of samples during the elimination phase, k
el and T½ could not be 
determined in 2 neonates and in 3 infants. In these patients, the mean k
el value of their age group 
was used for the calculation of those pharmacokinetic variables dependent on the k
el value. Values 
for V
ss
 were calculated using the noncompartmental equation: V
ss
 = dose x (AUMC/AUC2) – (T x 
dose/2 x AUC), where AUMC is the area under the first moment of the plasma concentration-time 
curve, and T the duration of infusion (Perrier et al 1982). The relationship of the CL, V
ss
, and T½ to 
the BSA was determined. The ratio of the plasma concentration of N-acetylamrinone to that of 
amrinone was determined and the area under this ratio-time curve from 0 to 60 hours [AUC(0-60)] 
and the total area (AUCtot) in each patient were calculated. The relationship between the CL of 
amrinone and the mean values of serum transaminases, and creatinine was determined. The 
concentration of amrinone in the dialysate was analyzed similarly as the plasma amrinone 
concentration. 
 
7. Statistical analysis 
 
Prior to study I, a power calculation for a 20 % difference in PVR index between the methods, with 
the probability of type α error of 5 % and a probability of type β error of 20 %, yielded a sample 
size of 100 patients. In this calculation, standard deviation (SD) of the changes expected was 
assumed to be 3.5 Wood units x m2. The agreement between the measured and predicted V• O2 
values was assessed by plotting the relative error of predicted V• O2 against the average of measured 
and predicted values using the Bland and Altman method (Bland et al 1986).  Analysis of variance 
was used to evaluate the influence of nominal variables, and stepwise linear regression was used to 
evaluate the influence of continuous variables on the precision of the predicted V• O2 in study I. The 
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group means between canopy and ventilator measurements were compared with Student’s unpaired 
t-test. The error of calculated V• O2 was compared to the error of the two NN estimates with 
Student’s t-test for means of two samples. Results are presented as mean ± SD and range.  
 
In study II, the pharmacokinetic parameters between the groups were compared using Student’s 
unpaired t-test. The results are presented as mean ± SD. The relationship of the CL, V
ss
, and T½ to 
the BSA, and between the CL of amrinone and the mean values of serum transaminases, and 
creatinine was determined by using Pearson’s correlation coefficient. 
 
Prior to studies III and IV a power calculation for a 20 % difference in cardiac index and PVR index 
with a probability of type α error of 5 % and a probability of type β error of 20 % yielded a sample 
size of 12 patients for each study group.  
 
The group means were compared with Student’s unpaired two-tailed t-test, and analysis of variance 
for repeated measures was used to compare hemodynamics between study groups in studies III and 
IV. Post hoc pairwise tests were performed for variables with significant differences in the analysis 
of variance in study III. The results of studies III and IV are presented as mean ± SD, and 95 % CI 
for mean values. 
 
In every study, the differences were considered statistically significant when the probability of the 
type α error was less than 5 %.  
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
The characteristics of patients that completed the studies are shown in Table 6. In study III, two of 
the 35 randomized neonates were excluded because of residual left-to-right shunts, one of them 
requiring reoperation on the second postoperative day. However, the treatment regimen in these two 
patients was not changed. Two other neonates were excluded because of postoperative 
hemodynamic difficulties requiring out-of- protocol treatment.  Of the included patients, left atrial 
data could not be obtained in one neonate in both groups because of catheter displacement.  Two 
patients in the dopamine-nitroglycerine group and one patient in the amrinone group required NO 
inhalation during the study period - their data during the NO therapy were excluded from analysis.  
All other data from these five patients were included.   Four neonates in the amrinone group and 
two neonates in the dopamine-nitroglycerine group had abnormal coronary anatomy. Two neonates 
in the dopamine-nitroglycerine group had coexisting coarctation of the aorta. Five neonates in the 
amrinone group and four neonates in the dopamine-nitroglycerine group had coexisting ventricular 
septal defect. 
 
In study IV, four of the randomized 32 infants were excluded, two because of severe pulmonary 
hypertension requiring extensive out-of- protocol management, one because of partial, rather than 
complete, AVSD, and one because of severe postoperative mitral insufficiency. Of the included 
patients, left atrial data could not be obtained from one infant in both groups because of catheter 
displacement.  One patient in the amrinone group required continuous NO inhalation for eleven 
hours during the study period; her data during the NO therapy were excluded from the analysis.  All 
other data from these three patients were included. One infant with Klinefelters`syndrome was 
included in dopamine-nitroglycerine group. 
 
Table 6. Patient characteristics. 
Study Number of 
patients 
Diagnosis Down’s 
syndrome 
Female/male Age (years) Weight (kg) BSA (m2) 
I 125 Various CHD 34/125 73/52 1.88 ± 2.09 9.0 ± 4.2 0.42 ± 0.15 
II 29 AVSD, TGA 14/29 12/17 0.18 ± 0.19 4.2 ± 0.8 0.24 ± 0.03 
III 31 TGA 0/31 11/20 0.02 ± 0.02 3.7 ± 0.5 0.22 ± 0.02 
IV 28 AVSD 25/28 20/8 0.33 ± 0.11 4.6 ± 0.7 0.26 ± 0.03 
Data is presented as mean ± standard deviation. 
Abbreviations: CHD, congenital heart disease; AVSD, atrioventricular septal defect; TGA, transposition of great 
arteries; BSA, body surface area. 
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1. Measured versus predicted oxygen consumption during preoperative cardiac 
catheterization in children with congenital heart disease (I) 
 
Of the 125 measurements, 84 were performed in spontaneously breathing patients using the canopy. 
The regression lines for measured V• O2 and V
• O2 predicted according to Lindahl (1989), plotted 
against weight are shown Figure 1.  The relative bias and precision of the V• O2 values predicted 
according to regression equation by Lindahl are presented in Figure 2a and the corresponding 
values using the regression equation by Wessel et al (1969) in Figure 2b. The relative biases of the 
predicted V• O2 and the precisions produced by the different methods are shown in Table 7. 
 
Since calculations based on the equation published by Wessel et al (1969) and Lundell et al (1996) 
resulted in poorer precision than those based on the equation published by Lindahl (1989), the 
subsequent comparisons were made using Lindahl´s equation (1989). The relationship between 
PVR index calculated using measured V• O2 and predicted V
• O2 is shown in Figure 3. Even though 
in three patients with left-to-right shunts, two of them with Down’s syndrome, and one patient with 
left heart downstream obstruction, the use of predicted V• O2 in calculation of PVR index would 
have resulted in overestimation of PVR index, all these patients underwent surgical correction 
successfully.  In four patients with Down’s syndrome and left-to-right shunts, the use of predicted V•
O2 would have underestimated the calculated PVR index.  One of these patients died of 
postoperative pulmonary hypertension; the others survived. 
 
Age, weight, gender, BSA, MAP, PAP, heart rate, hemoglobin or Q• p: Q• s ratio had no statistically 
significant influence on the error of predicted V• O2 when analyzed with analysis of variance and 
linear regression. Heart failure or type of cardiac malformation did not affect the error either. 
 
There was a statistically significant difference in the bias of the predicted V• O2 between 
measurements made with a canopy compared to those made in mechanically ventilated patients.  
The bias averaged 7 %,  (range -50 % to 43 %) in spontaneously breathing patients, and -5 %, 
(range -66 % to 30 %) in mechanically ventilated patients, (p <0.03). 
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The addition of other input variables than those found in published equations to the NN did not 
produce a marked improvement in the estimation of V• O2. Even though the NN estimated V
• O2 with 
higher precision, there was no statistically significant difference in the error of V• O2 calculated 
according to the equation published by Lindahl (1989), and the error of the NN estimates of V• O2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The regression lines for measured V• O2 values (ml/min), and predicted V• O2 values 
(ml/min) according to Lindahl (1989), plotted against weight (kg). Abbreviations: V• O2, oxygen 
consumption. 
 
 
Table 7. The relative biases of the predicted V• O2 and the precisions produced by the different 
methods. 
Method of producing predicted V
•
O2 values Bias of the predicted V
•
O2 (range) (%) 
Precision (%) 
Equation by Lindahl (1989) 3  (-66 to 43) ± 42  
Equation by Wessel et al (1969) 0  (- 69 to 39) ± 44  
Equation by Lundell et al (1996) - 16  (- 94 to 100) ± 51  
Neural network 6 (-19 to 30) ± 29 
Abbreviations: V
•
O2, oxygen consumption. 
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Figure 2a. The relative bias and precision of the predicted V• O2 values (ml/min) according to 
regression equation by Lindahl (1989). Abbreviations: V• O2, oxygen consumption. 
Figure 2b. The relative bias and precision of the predicted V• O2 values (ml/min) according to 
regression equation by Wessel et al (1969). Abbreviations: V• O2, oxygen consumption. 
  
 
 
 
 
 
 
 
 
 
 
Figure 3. The relationship between measured and predicted PVRI (Wood units x m2) according to 
Lindahl regression equation (1989). Abbreviations: PVRI, pulmonary vascular resistance index. 
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2. Pharmacokinetics of amrinone in neonates and infants after open-heart surgery for 
congenital heart disease (II) 
 
The plasma concentrations of amrinone in neonates and infants are presented in Figure 4. The 
amrinone plasma concentrations were between 1.5 to 6 µg/ml in all patients, even though they were 
approximately 30 % lower in infants than in neonates. The delay (mean ± SD, range) between the 
bolus dose of amrinone and start of the maintenance infusion was 26 ± 14 minutes (from 6 to 57 
minutes) in neonates and 11 ± 7 minutes (from 5 to 29 minutes) in infants. The difference of the 
delay was secondary to differences in the surgical technique and management of CPB in the two 
patient groups. The duration of the amrinone infusion in the neonates was 114 ± 45 hours (from 66 
to 216 hours) and that in the infants 120 ± 78 hours (from 42 to 342 hours). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plasma concentrations (µg/ml) of amrinone in 15 neonates (A) and in 14 infants (B) after 
a bolus dose of 2 mg/kg followed by a continuous infusion of 7.5 µg/kg/min of amrinone. Note the 
axis break at 1 hour to clarify the decrease of the plasma concentrations after the bolus dose of 
amrinone. In 1 neonate and in 1 infant, the duration of the infusion was longer than 200 hours. 
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Amrinone CL was statistically significantly lower, 2.4 ± 0.9 ml/kg/min, in neonates, compared with 
3.2 ± 1.2 ml/kg/min in infants (p <0.05). The V
ss
 was significantly smaller, 0.8 ± 0.6 l/kg, in 
neonates, when compared with 1.6 ± 1.1 l/kg in infants (p <0.05). The T½ was also significantly 
longer in neonates than in infants (10.7 ± 6.7 hours and 6.1 ± 1.4 hours, respectively, p <0.03). A 
linear correlation was detected between the CL of amrinone and the BSA (r =0.67; p <0.05) but not 
between the V
ss
 and the BSA or the T½ and the BSA. There was no linear correlation between 
amrinone CL and serum creatinine, or transaminases.  The ratio between plasma concentration of 
N-acetylamrinone and amrinone did not differ between neonates and infants. No patient had a 
detectable plasma concentration of N-glycolylamrinone.  
 
Peritoneal dialysis was required due to impaired urinary output in two neonates and two infants. 
The concentrations of amrinone in plasma and in the dialysate in these patients are shown in Figure 
5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Concentrations of amrinone in plasma (solid line) and in dialysate (dotted line) in 2 
neonates and in 2 infants requiring peritoneal dialysis. The bold line represents the plasma 
concentrations during peritoneal dialysis. 
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3. Amrinone versus dopamine-nitroglycerine after reconstructive surgery for congenital heart 
disease in neonates and infants (III, IV) 
 
There were no differences in the CPB time, aortic cross-clamp time, and circulatory arrest time 
between the study groups.  The cardiopulmonary variables of the groups during the study period are 
presented in Table 8.  
 
3.1. Systemic and pulmonary blood flow 
 
The Q• s and Q• p indexes of the neonates recorded during the study period are presented Figure 6. 
The Q• s index was significantly higher in the amrinone group, p < 0.04. The Q• p index was higher in 
the amrinone group, but not statistically significantly (p = 0.06). The post-hoc pairwise test revealed 
significant difference in the Q• s index at 4, 6 and 8 hours after separation from CPB between the 
groups. The Q• s and Q• p indexes of the infants recorded during the study period are presented in 
Figure 7.  The Q• s and Q• p indexes were significantly higher in the amrinone group, p < 0.03 and p < 
0.01, respectively. 
 
3.2. Systemic and pulmonary vascular resistance  
 
The SVR and PVR indexes of the neonates are shown in Figure 8. The SVR index was significantly 
lower in the amrinone group, p < 0.02. The PVR index was lower in the amrinone group, but not 
statistically significantly (p = 0.05). There was a significant difference in the SVR index at 4, 6, 8 
and 16 hours after discontinuation of CPB in the post-hoc pairwise test. The SVR and PVR indexes 
of the infants are shown in Figure 9. The SVR index was significantly lower in the amrinone group, 
p < 0.04. The PVR index was lower in the amrinone group, but not statistically significantly. 
 
3.3. Oxygen extraction ratio 
 
The O2ER in the dopamine-nitroglycerine group was higher in neonates (0.34 ± 0.08), and infants 
(0.41 ± 0.07), compared to the neonates (0.28 ± 0.06; p < 0.02) and infants (0.34 ± 0.08; p < 0.02) 
in the amrinone group. 
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Table 8. Cardiopulmonary variables of the study groups. 
 Amrinone (neonates) Dopamine-NTG 
(neonates) 
Amrinone (infants) 
 
Dopamine-NTG 
(infants) 
pHa 7.51 ± 0.07 7.51 ± 0.06 7.46 ± 0.06 7.46 ± 0.07 
PaCO2(kPa) 3.48 ± 0.62 3.33 ± 0.52 3.63 ± 0.71 3.78 ± 0.76 
PaO2/FiO2 23.4 ± 11.2 29.6 ± 10.6 39.3 ± 11.5 33.3 ± 11.5 
Heart rate (beat/min) 165 ± 16 164 ± 19 145 ± 16 146 ± 18 
Hemoglobin  (g/l) 155 ± 15 153 ±17 139 ± 16 135 ±14 
Rectal temperature (°C) 37.0 ± 0.7 37.0 ± 0.8 37.6 ± 0.5 37.6 ± 0.6 
Oxygen consumption
 
(ml/min/m2) 
109 ± 16 104 ± 16 177 ± 22 162 ± 21 
Mean blood pressure 
(mmHg) 
48 ± 6 52 ± 9 56 ± 9 57 ± 8 
Mean pulmonary artery 
pressure (mmHg) 
16 ± 3 17 ± 4 21 ± 5 20 ± 4 
Mean central venous 
pressure (mmHg) 
6 ± 2  6 ± 2 7 ± 2 7 ± 2 
Mean left atrial pressure 
(mmHg) 
6 ± 2 6 ± 2 6 ± 3 6 ± 2 
SaO2 (%) 95 ± 3 96 ± 3 98 ± 2 97 ± 2 
SpaO2 (%) 68 ± 7 64 ± 9 65 ± 8 58 ± 7* 
ScvO2 (%) 62 ± 9 59 ± 12  58 ± 10 52 ± 10 
SlaO2 (%) 95 ± 3 97 ± 2° 98 ± 2 97 ± 2 
Q• p: Q• s 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 
Epinephrine (patients) 12 15 8 5 
Epinephrine (ug/kg/min) 0.06 ± 0.04 0.06 ± 0.07 0.11 ± 0.07 0.04 ± 0.02 
Values are given as mean ± standard deviation.   
Abbreviations: NTG, nitroglycerine; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; FIO2, 
fraction of oxygen in inspired gas; SaO2, arterial oxyhemoglobin saturation; SpaO2, pulmonary artery oxyhemoglobin 
saturation; ScvO2, central venous oxyhemoglobin saturation; SlaO2 , left atrial oxyhemoglobin saturation; Q
•
p: Q• s, 
pulmonary-to-systemic flow ratio. 
*P< 0.006 in infants, °P< 0.009 in neonates 
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Figure 6.  Systemic (Q• sI) and pulmonary (Q• pI) flow indexes from 4 to18 hours after separation 
from cardiopulmonary bypass in neonates.  Values are given as mean ± 95 % confidence interval.  
Abbreviations: D+N, combination of dopamine and nitroglycerine; NS, not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Systemic (Q• sI) and pulmonary (Q• pI) flow indexes from 4 to18 hours after separation 
from cardiopulmonary bypass in infants.  Values are given as mean ± 95 % confidence interval.  
Abbreviations: D+N, combination of dopamine and nitroglycerine 
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Figure 8.  Systemic (SVRI) and pulmonary (PVRI) vascular resistance indexes from 4 to 18 hours 
after separation from cardiopulmonary bypass in neonates.  Values are given as mean ± 95 % 
confidence interval.  Abbreviations: D+N, combination of dopamine and nitroglycerine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Systemic (SVRI) and pulmonary (PVRI) vascular resistance indexes from 4 to 18 hours 
after separation from cardiopulmonary bypass in infants.  Values are given as mean ± 95 % 
confidence interval.  Abbreviations: D+N, combination of dopamine and nitroglycerine; NS, not 
significant. 
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3.4. Adverse effects 
 
The average preoperative platelet count was in the normal range in both neonatal groups and infant 
groups.  Eight neonates in the amrinone group and six neonates in the dopamine-nitroglycerine 
group received platelet transfusions during the operation in accordance with the institutional 
guidelines for hemostasis in neonates. The platelet counts from the day of operation to the fourth 
postoperative day are shown in Figure 10a.  There was a significant difference in the platelet counts 
of the third and fourth postoperative day in the post-hoc pairwise analysis. Two neonates in the 
dopamine-nitroglycerine group were transfused with platelets during the second and the third 
postoperative days.  In the amrinone group, a platelet transfusion was given to one neonate on the 
sixth postoperative day. No significant difference was observed in blood drainage volumes up to the 
third postoperative day.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10a.  Platelet counts from the day of surgery to the fourth postoperative day in neonates.  
Values are given as mean ± 95 % confidence interval. Abbreviations: D+N, combination of 
dopamine and nitroglycerine. 
 
One infant in the amrinone group received platelet transfusion during the surgery because of 
difficulties in achieving surgical hemostasis despite normal platelet count.  Two infants in the 
amrinone group received platelet transfusions during the second and the third postoperative days 
due to platelet counts of 20 x 109/l in both cases.  In the dopamine-nitroglycerine group, a platelet 
transfusion was given to one infant on the first postoperative day (platelet count 51 x 109/l).  The 
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platelet counts from the day of operation to the fourth postoperative day are presented in Figure 
10b. No significant difference was observed in blood drainage volumes in infants up to the first 
postoperative day.   
 
The average pre- and postoperative serum creatinine values were in the normal range with no 
difference observed between the study groups in neonates and infants.  There was no significant 
difference in the serum transaminase values between the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10b.  Platelet counts from the day of surgery to the fourth postoperative day in infants.  
Values are given as mean ± 95 % confidence interval. Abbreviations: D+N, combination of 
dopamine and nitroglycerine. 
 
3.5. Perioperative morbidity and mortality 
 
Two patients in both neonatal groups required delayed sternal closure because of myocardial 
edema. In two additional neonates in the dopamine-nitroglycerine group, the sternum was reopened 
on the fourth postoperative day because of cardiac tamponade after removal of the pulmonary and 
left atrial catheters. Peritoneal dialysis was required in three neonates in the amrinone group and 
four neonates in the dopamine-nitroglycerine group because of reduced diuresis during the study 
period. 
 
Separation from CPB was complicated by right ventricular dysfunction and hypotension that was 
probably aggravated by coronary artery air in three infants in the amrinone group. No intracoronary 
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air problems were observed in the dopamine-nitroglycerine group. The epinephrine dose received 
by those three patients was higher (0.15-0.23 µg/kg/min) than that of other study patients, (0.06 ± 
0.03 µg/kg/min in the amrinone group, 0.04 ± 0.02 µg/kg/min in the dopamine-nitroglycerine 
group; NS).  However, the hemodynamic trends observed in the entire study group were not 
changed during the reanalysis of the data with these three patients excluded. Hemorrhagic problems 
after the operation were not seen in any infant.  Five patients in both infant groups required 
peritoneal dialysis because of oliguria during the study. There was no difference in ascites 
production between the groups. 
 
There were no statistically significant differences observed in the need for mechanical ventilation 
between the groups of neonates (71 ± 37 hours, from 27 to 149 hours, in the amrinone group and 92 
± 68 hours, from 23 to 249 hours in the dopamine-nitroglycerine group), and infants (81 ± 56 hours, 
from 23 to 187 hours, in the amrinone group and 89 ± 70 hours, from 25 to 189 hours in the 
dopamine-nitroglycerine group).  In neonates, the length of stay in the ICU was 5 ± 2 days (from 3 
to 11 days) in the amrinone group and 6 ± 4 days (from 3 to 16 days) in the dopamine-
nitroglycerine group.  The duration of intensive care period in infants was 5 ± 3 days (from 2 to 14 
days) in the amrinone group and 7 ± 3 days (from 3 to 11 days) in the dopamine-nitroglycerine 
group (NS). The total duration of hospitalization was 12 ± 3 days, from 8 to 18 days, in the neonates 
of the amrinone group and 12 ± 5 days, from 6 to 26 days, in the neonates of the dopamine-
nitroglycerine group. The hospitalization time in infants was 14 ± 6 in both groups, ranging from 6 
to 26 days in the amrinone group and from 7 to 28 days in the dopamine-nitroglycerine group. 
 
One neonate in the amrinone group died on the eight postoperative day because of septicemia 
caused by strangulation of the ileum. There was no mortality among the infants in the study. 
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DISCUSSION 
 
This series of four studies was designed to evaluate cardiovascular management in children 
undergoing open-heart surgery. The utility of linear regression equations and artificial NN in V• O2 
prediction was elucidated at preoperative cardiac catheterization in patients with CHD. The efficacy 
and safety of amrinone and a combination of dopamine and nitroglycerine in neonates and infants 
were assessed after reconstructive surgery for CHD.  Amrinone pharmacokinetics were also 
examined to ensure adequate amrinone dosing, and to clarify the distribution and elimination of 
amrinone and its metabolites in these patients.  
 
The first study demonstrated that nonlinear method based on artificial intelligence NN did not 
statistically significantly increase the accuracy of predicted V• O2 when variables used in linear 
regression equations were employed. In study II, both the CL and the V
ss
 were lower and the T½ 
longer in neonates than in infants. No significant difference in the rate of acetylation between these 
age groups was observed. Studies III and IV are the first ones to evaluate the hemodynamic effects 
amrinone and dopamine-nitroglycerine in a prospective, double-blind manner. The results show that 
both amrinone and a combination of dopamine and nitroglycerine provide acceptable circulatory 
support in neonates after reconstructive surgery for TGA (III), and in infants after reconstructive 
surgery for complete AVSD (IV). However, the hemodynamic profile was more favorable in 
patients receiving amrinone: the Q• s index was significantly higher, and the peripheral vascular 
resistances, as well as the O2ER values were significantly lower in the amrinone group compared to 
the dopamine-nitroglycerine group.   
 
1. Determination of oxygen consumption
 
in children with congenital heart disease  
 
Indirect calorimetry is a method in which the type and rate of substrate utilization and energy 
metabolism are estimated from measurement of gas exchange. When carbohydrate, fat, and protein 
are oxidized, O2 is consumed, and heat and CO2 produced.  However, anaerobic metabolism, as 
well as differences in the produced and exhaled CO2 may affect the indirect calorimetry 
measurements (Ferrannini 1988).
 
Routine measurement equipment for V• O2 in children has been 
available only recently. Methods using a pneumotachograph, a Douglas bag, an infrared CO2 
analyzer, a mass spectrometer, as well as a paramagnetic O2 analyzer have been used in V
• O2 
determination (Wessel et al 1969, Lindahl 1989, Lundell et al 1996). These methods have small 
interobservational variation (Lindahl 1989, Lundell et al 1996). However, these equipment require 
frequent calibration to give reliable results. Furthermore, the measurements during mechanical 
ventilation and when high FIO2 are needed may be cumbersome. With metabolic monitor Deltatrac, 
(Datex-Engström, Helsinki, Finland), the measurements can be made both in spontaneously 
breathing and mechanically ventilated patients, even when a high fraction of inspired oxygen is 
used (Meriläinen 1987). With this device, the mean V• O2 difference has been shown to average -3.2 
% and the precision ± 23 % when compared to mass spectrometry and wet gas spirometry in 
ventilated pediatric patients with V• O2 ranging from 20 to 50 ml/min. The variability of V
• O2 
measurement was further reduced to ± 12.7 % if measurements with inspiratory and expiratory O2 
fraction difference and mixed expiratory CO2 fraction below 0.03, and FIO2 higher than 0.6 were 
excluded.  The device has not been validated for flows under 20 ml/min (Weyland et al 1994). 
However, when studying mechanically ventilated patients, cuffed tracheal tubes to prevent gas loss 
from the breathing circuit are often necessary for reliable results (Chwals et al 1992). Heart failure 
associated with left-to-right shunts has been shown to increase V• O2, probably due to increased 
sympathetic activity  (Kennaird 1976). In addition, physical activity state, level of sedation and 
changes in body temperature during the measurement affect V• O2 (Baum et al 1967, Wessel et al 
1969, Fixler et al 1974, Shapiro et al 1966).  
 
The V• O2 has been found to be proportional to body weight in healthy, spontaneously breathing 
anesthetized children and in children with CHD during mechanical ventilation. No differences were 
observed in V• O2 in children with and without CHD (Lindahl 1989). Despite differences in methods 
and study populations, the regression lines of study I and Lindahl’s study (1989) describing 
measured V• O2 as a function of body weight were remarkably similar (Figure 1). However, neither 
of the regression equations were accurate in predicting V• O2 - despite the small relative bias of the 
predicted V• O2 the degree of agreement was not high between the measured and predicted V
• O2 
values (Figure 2a). In 6 % of children in study I the use of predicted V• O2 values according to 
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equation published by Lindahl (1989) would have result in misestimation of calculated PVR index 
when plotted against PVR index from measured V• O2 (Figure 3). Even though the number of these 
children is small, and the management decisions of CHD hardly depend on any cut-off value of 
PVR index, the use of predicted values may lead to inaccurate evaluation of the hemodynamic 
status in an individual patient. Oxygen uptake and BSA were found to have a linear relationship in 
sedated, spontaneously breathing patients with CHD (Wessel et al 1969). In sedated children with 
CHD under three years of age, who were breathing room air spontaneously, the body dimensions 
and heart rate influenced V• O2. In older children, gender, BSA, and heart rate affected V
• O2 
significantly (Lundell et al 1996). Agreement between the measured and predicted V• O2 according 
to these equations was not higher when compared with the equation created by Lindahl (1989). The 
use of an artificial intelligence NN, a pattern recognition technique that does not assume or require 
a mathematical relationship between the independent and dependent variables, produced less 
variability in its estimate of V• O2 than the models that assume linear effects of these variables on V
•
O2, even when the same variables were used. However, the addition of other variables describing 
the patient as input variables to NN did not make its prediction any more accurate from that based 
on age, gender, height, weight and heart rate.  Furthermore, the difference in the error of V• O2 
calculated according to the equation published by Lindahl (1989), and the error of the NN estimates 
of V• O2 was not statistically significant.  Some variability in the error of measured and predicted V
•
O2 may inevitably arise from the V
• O2 measurements performed with metabolic monitor Deltatrac, 
especially when 67 % of the measurements in the study I were performed in spontaneously 
breathing patients using the canopy mode.  The large relative error of predicted V• O2 represents the 
large interindividual variation in circulatory compromise and metabolic rate in the patients of the 
study I. Biological variation of the patients may have effected variation in V• O2, even though no 
statistically significant influence of the tested variables on the error of predicted V• O2 was found. 
Variation in body temperature also may have introduced variation in V• O2 in this study (Shapiro et 
al 1966). The fact that the increased number of input variables describing the patient to NN did not 
make its prediction of V• O2 any more accurate than that based on variables found relevant in linear 
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regression equations, suggests that these methods of V• O2 prediction may be of limited value in the 
even more complex setting of recovery from pediatric open-heart surgery. 
 
 In both studies III and IV, administration of amrinone was associated with a slightly although not 
statistically significantly higher V• O2 than the combination of dopamine and nitroglycerine.  
However, no significant thermogenic effect of amrinone has been shown in previous studies 
(Robinson et al 1993, Ruttimann et al 1994). Furthermore, there was no statistically significant 
difference in the epinephrine dose required in amrinone and dopamine-nitroglycerine groups. The 
higher cardiac output in the amrinone groups was associated with improved overall O2 dynamics in 
neonates as well as in infants.  In neonates of study III, the V• O2 values were found to be rather low. 
A gas leak in the breathing circuit can produce an underestimate of V• O2 (Chwals et al 1992). 
However, cuffed tracheal tubes were used to prevent gas loss from the circuit in the patients of the 
present study.  Hyperventilation and alkalosis induced in the neonates may have affected the V• CO2 
measurements (Ferrannini 1988). Sedation and full ventilatory support may also have influenced the 
metabolic rate of our patients, resulting in lower V• O2 values than reported in spontaneously 
breathing patients in this age group (Lundell et al 1996). The significant difference in the V• O2 
between spontaneously breathing and mechanically ventilated patients despite stable conditions in 
study I further supports this contention. Measurement errors may have affected especially some of 
the V• O2 values observed in the neonates of study III, as the measured values were near the lower 
limits of validation (Weyland et al 1994).  
 
2. Amrinone pharmacokinetics in neonates and infants 
 
In previous studies, the pharmacokinetics of amrinone in children have been examined in 
heterogeneous patient populations.  Therefore, little is known about amrinone pharmacokinetics in 
neonates during the first four weeks of life (Lawless et al 1989, Allen-Web et al 1994, Williams et 
al 1995).  In study II, both the CL and the V
ss
 were smaller and the T½ longer in neonates than in 
infants. The results of the present study support the observations in previous studies despite the 
methodological differences (Lawless et al 1989, Allen-Web et al 1994, Sorensen 1996). However, 
Lawless et al (1989) did not observe any differences in Vd between neonates and infants. The 
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authors determined the CL by dividing the infusion rate by the plasma concentration of amrinone at 
the end of the infusion and calculated the Vd during the elimination phase instead of the V
ss
 used in 
the present study. Although this study was not planned for elucidation of concentration-response 
relationship in children, the amrinone plasma concentrations, that were found to be approximately 
30 % lower in infants than in neonates, resulted in steady-state plasma concentrations of 1.5 to 6 
µg/ml, which have been shown to be effective in adults (Edelson et al 1981). 
 
Amrinone is metabolized by acetylation and glucuronidation in the liver, while 40 % is excreted in 
the urine (Kullberg et al 1981, Steinberg et al 1994). In adult cardiac surgical patients, plasma 
protein binding of amrinone is 21 %, and it is not affected by surgery and CPB. Further, the 
pharmacokinetic profile in these adult patients was not significantly affected by CPB when 
compared with healthy volunteers (Bailey et al 1991). There is lack of information on the effects of 
anesthesia, surgery and CPB on the pharmacokinetics of amrinone in children with CHD. In 
previous studies, the pharmacokinetics have been examined mainly in the ICU in heterogeneous 
groups of children under different anesthetic management  (Lawless et al 1989, Allen-Web et al 
1994). The plasma protein binding of amrinone in young children with low plasma protein levels 
has not been reported. However, in children undergoing cardiac surgery, a reduction in the Vd of 
amrinone is suggested during hypothermic CPB when compared with values found during the 
postoperative period.  Furthermore, approximately 20 % of the loading dose administered into the 
CPB circuit becomes unavailable secondary to sequestration in bypass equipment (Williams et al 
1995). These factors may affect the total plasma concentration of amrinone during surgery.  The 
renally excreted N-acetylamrinone, the major metabolite, accounts only 2 % of the total dose of 
amrinone in adults (Kullberg et al 1981). Slow acetylation of caffeine and sulfadimidine has been 
found in young children (Szorady et al 1987, Pariente-Khayat et al 1991). However, no difference 
was observed in the ratio of the plasma concentration of N-acetylamrinone to that of amrinone in 
the present study indicating no significant differences in the rate of acetylation between these age 
groups. This finding confirms previous results (Allen-Webb et al 1994) and suggests that the 
maturation of hepatic amrinone N-acetylation capacity is complete already during the first weeks of 
life. Allen-Webb et al (1994) have shown in one neonate that renal CL accounts for the majority of 
total amrinone CL. Therefore, the slow elimination of amrinone in neonates may be mainly due to 
their immature renal function. The fact that amrinone plasma concentration did not increase in 
patients with renal failure and peritoneal dialysis, indirectly supports the contention that peritoneal 
dialysis contributed to the elimination of amrinone. However, it is also possible that elimination of 
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amrinone through alternative metabolic routes increased in these patients. Unfortunately, the design 
of the present study does not allow any conclusions on this matter. 
 
 
3. Hemodynamics in neonates and infants during amrinone or dopamine-nitroglycerine 
administration after reconstructive surgery for congenital heart disease  
 
The cardiac pathophysiology of neonates with TGA and infants with complete AVSD is 
characterized by two major hemodynamic problems after reconstructive surgery: low cardiac output 
and reactive pulmonary vasculature. Since patients with TGA and AVSD represent two distinct age 
groups and maturational states of the cardiovascular system, they were separated in the present 
study.  
 
Dopamine, epinephrine and nitroglycerine are frequently used in vasoactive support in these 
patients. Dopamine is typically infused from 5 to 10 µg/kg/min, nitroglycerine from 0.5 to 10 
µg/kg/min, and epinephrine form 0.05 to 0.4 µg/kg/min in many institutions (Wernovsky et al 
1995a, Wernovsky et al 1995b, Bando et al 1995, Bando et al 1996).  Amrinone is often infused 
from 5 to 10 µg/kg/min (Lawless et al 1989, Wernovsky et al 1995b). The relative potency of the 
vasoactive agents in the present study is difficult to establish. Neonates and infants require higher 
doses of dopamine to achieve significant increase in cardiac output than older children or adult 
patients after cardiac surgery (Perez et al 1986, Outwater et al 1990, Bhatt-Mehta et al 1991). In 
addition to pulmonary vasodilatation, nitroglycerine may induce also systemic vasodilatation, which 
may be especially harmful if the right ventricle is failing  (Burrows et al 1986). Dosing of amrinone 
according to guidelines established to achieve therapeutic serum concentrations in adults has 
produced a wide range of blood levels in children, all associated with clinically acceptable cardiac 
performance (Edelson et al 1981, Lawless et al 1989, Allen-Webb et al 1994).  The responses to 
catecholamines and PDE inhibitors also may be altered by chronic heart failure and β-adrenoceptor 
down-regulation and uncoupling. In many children with CHD, most of the β-adrenoceptor down 
regulation is β1- subtype selective, but in neonates with TGA additional significant β2-
adrenoceptor down- regulation may be present (Kozlik-Feldmann et al 1993). In the present study, 
the cardiac output was significantly higher in the amrinone groups. The dose of epinephrine 
required both in neonates and infants was rather high, but not statistically significantly different 
between the groups. A higher dose of dopamine may have provided some increase in the cardiac 
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output in the patients in dopamine-nitroglycerine groups. However, the ability of β-adrenergic 
agonists to stimulate adenylate cyclase is decreased in young children, while there is no age-
dependency in the PDE inhibitor effect (Foged et al 1990, Baum et al 1997). Therefore, it is 
unlikely that increased dose of dopamine would have resulted in significantly improved overall 
cardiac performance in the dopamine-nitroglycerine groups, because even the combined effect of 
dopamine and epinephrine on β-adrenoceptors, supplemented with nitroglycerine, failed to improve 
it more than the combination of amrinone and epinephrine. Further, the argument that an increase in 
the vasodilator dose in the dopamine-nitroglycerine groups would have produced higher cardiac 
output is countered by the finding in a previous study, in which amrinone administration resulted in 
increased cardiac output per unit decrease in afterload secondary to positive inotropic effect when 
compared with a pure vasodilator (Bailey et al 1997).      
 
Inotropic agents are often evaluated by measuring hemodynamic response to a stepwise increase in 
dose (Berner et al 1990, Outwater et al 1990). This approach was not considered possible in studies 
III and IV, because effective levels of vasoactive agents often are already required for separation 
from CPB in neonates with TGA and infants with AVSD (Wernovsky et al 1995a, Bando et al 
1995). Moreover, baseline values obtained shortly after separation from CPB at the time of 
cardiovascular instability may have limited validity.  A cross-over design would allow the 
comparison of treatments on the same subjects (Hills et al 1979). However, the effect of time on the 
postoperative recovery would probably confound the comparison of two vasoactive regimens, as the 
postoperative course of these patients is often characterized by a transitory decrease in cardiac 
output during the first postoperative night (Wernovsky et al 1995a). Furthermore, the T½ of 
amrinone significantly exceeds that of dopamine and nitroglycerine, making random-order 
crossover impossible  (Lawless et al 1988, Notterman et al 1990, Bhatt-Mehta et al 1991, Allen-
Webb et al 1994).  
 
The use of catecholamines to enhance cardiac output after pediatric cardiac surgery is compromised 
by a potential increase in PVR (Booker et al 1995).  In study III, an open–label epinephrine infusion 
was administered postoperatively in 12 neonates in the amrinone group, and 15 neonates in the 
dopamine-nitroglycerine group. Eight infants were given epinephrine in the amrinone group, and 
five infants in the dopamine-nitroglycerine group in study IV.  In both neonates and infants, there 
was a tendency for lower PVR index in the amrinone group, which did not reach statistical 
significance. In the infants, the Q• p was significantly higher in the amrinone group while PAP 
showed no difference between the groups, suggesting a fall in the resistance of pulmonary 
vasculature in infants receiving amrinone. In the neonates, the Q• s index was statistically 
significantly higher in the amrinone group, while no significant difference was observed in Q• p: Q• s 
between the groups.  Therefore, to claim absence of a difference in pulmonary hemodynamics 
between amrinone and dopamine-nitroglycerine on the basis of this study in neonates would carry a 
high risk of a type β statistical error. Even though the administration epinephrine infusion through 
the proximal lumen of the central venous line may affect the pulmonary vasodilating effects of the 
study regimen, extra left atrial lines were not inserted in these patients to avoid this phenomenon 
(Fullerton et al 1993), but the drugs were administered following the routine clinical practice of 
most institutions, including ours. 
 
The SVR index in the amrinone group was significantly lower than in the dopamine-nitroglycerine 
group while there was no difference in the left and right atrial pressures, suggesting similar volume 
loading in all study groups of neonates (III) and infants (IV). Despite the lower SVR index in 
amrinone group, no difference in the MAP was observed between the study groups. The need for 
volume loading during amrinone administration has been reported previously (Lynn et al 1993, 
Bailey et al 1997). However, the loading dose of amrinone in the present study was given into the 
venous reservoir of the bypass circuit just prior to removal of the aortic cross-clamp.  This 
technique of amrinone administration may be beneficial in avoiding the possible reduction of MAP 
and coronary circulation in these patients, even though some of the loading dose may become 
bound to the bypass circuit (Williams et al 1995). The average left atrial oxyhemoglobin saturation 
(SlaO2) was significantly lower in the neonates receiving amrinone, but not in infants under same 
medication, when compared with dopamine-nitroglycerine groups. The low SlaO2 in neonates may 
result from more pronounced intrapulmonary shunting associated with CPB, further accelerated by 
the vasodilatory effects of amrinone (Kirklin et al 1983). However, this phenomenon proved not to 
be deleterious in the neonates, as the higher cardiac output was associated with more favorable 
O2ER in the amrinone group.  
 
The principal side effect of prolonged amrinone therapy is thrombocytopenia secondary to 
amrinones effect on megakaryocytes or platelets, which decreases platelet survival (Ross et al 
1993). Even in the present study, low platelet counts in the amrinone group were observed up to the 
fourth postoperative day both in neonates and infants.  However, the lower platelet counts in the 
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amrinone group were not associated with increased postoperative blood loss. The two neonates, 
who had their sternum reopened to control bleeding after removal of pulmonary artery and left atrial 
lines, were receiving dopamine and nitroglycerine. 
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SUMMARY AND CONCLUSIONS 
 
Postoperative cardiovascular care of the patients with CHD is often complicated by low cardiac 
output and reactive pulmonary vasculature. In addition to the underlying cardiac pathophysiology, 
preoperative hemodynamic status, surgery and conduction of CPB, as well as anesthetic 
management affect postoperative cardiac performance. Furthermore, the response to vasoactive 
regimen may vary with the underlying cardiac defect, age, and degree of heart failure. The present 
study was conducted to evaluate cardiovascular management in children undergoing open-heart 
surgery. The utility of linear regression equations and nonlinear artificial intelligence NN in V• O2 
prediction was evaluated at preoperative cardiac catheterization by comparing measured and 
predicted V• O2 in a group of children with CHD (I). Pharmacokinetics of amrinone in neonates and 
infants after open-heart surgery for CHD (II) were also examined to ensure adequate amrinone 
dosing and to clarify the distribution and elimination of amrinone and its metabolites in these 
patients. Finally, the efficacy and safety of amrinone and a combination of dopamine and 
nitroglycerine was assessed in neonates after arterial switch operation for TGA, and in infants after 
reconstructive surgery for complete AVSD, during the first 18 postoperative hours in the ICU (III, 
IV).  
 
In study I, 125 children with CHD undergoing cardiac catheterizations were studied retrospectively. 
The V• O2 was measured using indirect calorimetry. The predicted values were calculated from 
regression equations by Lindahl (1989), Wessel et al (1969), and Lundell et al (1996). Influence of 
age, gender, weight, height, cardiac malformation, heart failure, heart rate, hemoglobin, MAP, PAP, 
and Q• p: Q• s on the precision of the predicted V• O2 were evaluated. An artificial NN was employed 
to produce an estimate of V• O2 using the variables found in the published regression equations as 
well as other variables describing the patient. Lindahl´s equations produced the highest precision (± 
42 %) of the regression-based estimates. The corresponding average bias of the predicted V• O2 was 
3 % (range from –66 % to 43 %). When equations by Wessel et al (1969) and Lundell et al (1996) 
were used, the bias and precision were 0 % (range from –69 % to 39 %) and ± 44 %, and –16 % 
(range from –94 % to 100 %) and ± 51 %, respectively. When the NN was used, the bias was 6 % 
(range from –19 % to 30 %) and precision  ± 29 %. Even though the NN estimated V• O2 with higher 
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precision, there was no statistically significant difference in the error of V• O2 calculated according 
to the equation published by Lindahl (1989), and the error of the NN estimates of V• O2. 
 
Fifteen neonates with TGA and 14 infants with AVSD participated in a prospective study (II) after 
reconstructive surgery. Blood samples to determine plasma concentrations of amrinone, N-
acetylamrinone, and N-glycolylamrinone were drawn before amrinone administration, after the 
loading dose of 2 mg/kg given during the CPB, and every 6 hours during the maintenance infusion 
of 7.5 µg/kg/min, and until 48 hours after cessation of the infusion. The amrinone plasma 
concentrations were between 1.5 to 6 µg/ml in all patients, even though they were approximately 30 
% lower in infants than in neonates.  Amrinone CL was significantly lower, 2.4 ± 0.9 ml/kg/min, in 
neonates, compared with 3.2 ± 1.2 ml/kg/min in infants (p < 0.05). The V
ss
 was significantly 
smaller, 0.8 ± 0.6 l/kg, in neonates, when compared with 1.6 ± 1.1 l/kg in infants (p < 0.05). The T½ 
was also significantly longer in neonates than in infants (10.7 ± 6.7 hours and 6.1 ± 1.4 hours, 
respectively, p < 0.03). The correlation between amrinone CL and BSA was linear. The ratio 
between plasma concentration of N-acetylamrinone and amrinone did not differ between neonates 
and infants. No patient had a detectable plasma concentration of N-glycolylamrinone 
 
In studies III and IV, 35 neonates and 32 infants participated in prospective, randomized, double 
blind studies. Amrinone loading dose, 2 mg/kg, was followed by a maintenance infusion, 7.5 
µg/kg/min in 16 neonates and 17 infants before separation from the CPB. The remaining patients 
received a combination of dopamine, 5 µg/kg/min, and nitroglycerine, 1 µg/kg/min. An open-label 
epinephrine infusion and inhaled NO were available for further vasoactive support. The circulatory 
state of the patients was evaluated two-hourly from four to 18 hours after CPB using the Fick 
principle and measured V• O2 values. The Q• s index was significantly higher in the amrinone groups 
when compared with dopamine-nitroglycerine groups (in neonates 1.7 ± 0.5 l/min/m2, and 1.4 ± 0.4 
l/min/m2, respectively, p < 0.04, and in infants 2.5 ± 0.7 l/min/m2, and 2.0 ± 0.6 l/min/m2, 
respectively, p < 0.03). The SVR index was significantly lower in the amrinone groups than in the 
dopamine-nitroglycerine groups (in neonates 26 ± 8 Wood units x m2, and 35 ± 12 Wood units x 
m2, respectively, p <0.02, and in infants 21 ± 6 Wood units x m2, and 27 ± 8 Wood units x m2, 
respectively, p <0.04).   The O2ER was also significantly lower in the amrinone groups compared 
with the dopamine-nitroglycerine groups (in neonates 0.28 ± 0.06, and 0.34 ± 0.08, respectively, p < 
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0.02, and in infants 0.34 ± 0.08, and 0.41 ± 0.07, respectively, p < 0.02). The PVR index was lower 
in the amrinone groups than in the dopamine-nitroglycerine groups, but not statistically 
significantly (in neonates 5.5 ± 1.9 Wood units x m2, and 7.9 ± 4.2 Wood units x m2, respectively, 
p =0.05, and in infants 5.3 ± 2.0 Wood units x m2, and 7.1 ± 3.0 Wood units x m2, respectively). 
There was no statistically significant difference in the epinephrine dose required in both groups of 
neonates and infants. Platelet counts were significantly lower in the amrinone groups, but no 
difference in blood loss or hemorrhagic complications were observed between the study groups. 
The need for mechanical ventilation in neonates was 71 ± 37 hours, from 27 to 149 hours, in the 
amrinone group and 92 ± 68 hours, from 23 to 249 hours, in the dopamine-nitroglycerine group, 
and in infants 81 ± 56 hours, from 23 to 187 hours, in the amrinone group and 89 ± 70 hours, from 
25 to 189 hours, in the dopamine-nitroglycerine group. In neonates, the length of stay in the ICU 
was 5 ± 2 days (from 3 to 11 days) in the amrinone group and 6 ± 4 days (from 3 to 16 days) in the 
dopamine-nitroglycerine group.  The duration of intensive care period in infants was 5 ± 3 days 
(from 2 to 14 days) in the amrinone group and 7 ± 3 days (from 3 to 11 days) in the dopamine-
nitroglycerine group. The total duration of hospitalization was 12 ± 3 days, from 8 to 18 days, in the 
neonates of the amrinone group and 12 ± 5 days, from 6 to 26 days, in the neonates of the 
dopamine-nitroglycerine group. The hospitalization time in infants was 14 ± 6 in both groups, 
ranging from 6 to 26 days in the amrinone group and from 7 to 28 days in the dopamine-
nitroglycerine group. One neonate in the amrinone group died on the eight postoperative day 
because of septicemia caused by strangulation of the ileum. There was no mortality among the 
infants in the study. 
 
The results presented here allow the following conclusions to be made: 
1.The methods based on artificial intelligence NN do not provide statistically significantly higher 
agreement in preoperative V• O2 prediction than the nomograms based on linear regression technique 
in patients with CHD.  If predicted values are used, the large interindividual biological variation in 
these patients should be taken into account.  The measurement of V• O2, even though subject to 
measurement errors, is preferable in the hemodynamic evaluation of these patients. 
 
2. Amrinone is eliminated at a slower rate in neonates than in infants. The rate of acetylation of 
amrinone appears to be similar; the differences in the elimination capacity of amrinone are mainly 
due to the immature renal function in neonates. 
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3. Use of either amrinone or the combination of dopamine and nitroglycerine, supplemented with 
epinephrine, results in acceptable cardiovascular support in neonates recovering from arterial switch 
operations and in infants after reconstructive surgery for AVSD.  However, amrinone provides a 
higher cardiac output, lower peripheral vascular resistance, and more favorable O2 dynamics in 
patients prone to low cardiac output and increased PVR. Amrinone administration results in lower 
platelet counts than administration of dopamine and nitroglycerine with no difference in blood loss 
or hemorrhagic complications. 
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